Review

Open Access

SF-1 a key player in the development and differentiation of steroidogenic tissues

Pierre Val, Anne-Marie Lefrançois-Martinez*, Georges Veyssière and Antoine Martinez

Address: UMR CNRS 6547, Physiologie Comparée et Endocrinologie Moléculaire, Université Blaise Pascal, Clermont II, Complexe Universitaire des Cèzeaux, 24 avenue des Landais, 63177 Aubière Cedex, France

Email: Pierre Val - pierre.val@geem.univ-bpclermont.fr; Anne-Marie Lefrançois-Martinez* - a-marie.lefrancois-martinez@univ-bpclermont.fr; Georges Veyssière - georges.veyssiere@univ-bpclermont.fr; Antoine Martinez - antoine.martinez@univ-bpclermont.fr

* Corresponding author

Published: 18 September 2003

Received: 11 August 2003

Nuclear Receptor 2003, 1:8

Accepted: 18 September 2003

This article is available from: <http://www.nuclear-receptor.com/content/1/1/8>

© 2003 Val et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

Abstract

Since its discovery in the early 1990s, the orphan nuclear receptor SF-1 has been attributed a central role in the development and differentiation of steroidogenic tissues. SF-1 controls the expression of all the steroidogenic enzymes and cholesterol transporters required for steroidogenesis as well as the expression of steroidogenesis-stimulating hormones and their cognate receptors. SF-1 is also an essential regulator of genes involved in the sex determination cascade. The study of SF-1 null mice and of human mutants has been of great value to demonstrate the essential role of this factor in vivo, although the complete adrenal and gonadal agenesis in knock-out animals has impeded studies of its function as a transcriptional regulator. In particular, the role of SF-1 in the hormonal responsiveness of steroidogenic genes promoters is still a subject of debate. This extensive review takes into account recent data obtained from SF-1 haploinsufficient mice, pituitary-specific knock-outs and from transgenic mice experiments carried out with SF-1 target gene promoters. It also summarizes the pros and cons regarding the presumed role of SF-1 in cAMP signalling.

Review

SF-1 general characteristics

A steroidogenic-tissue enriched factor

While trying to uncover the molecular mechanisms controlling steroidogenic genes expression, two independent research teams identified an AGGTCA (Ad4) motif in the promoter region of these genes that was able to bind a putative member of the nuclear receptor superfamily [1,2]. This 53 kDa protein called Ad4BP (Adrenal 4 Binding Protein) or SF-1 (Steroidogenic Factor 1) is encoded by a cDNA that was successively cloned by the two teams [1,3] and is specifically expressed in steroidogenic tissues [1]. SF-1 shows high homology with the drosophila Ftz-F1

transcription factor, which controls *fushi tarazu* homeotic gene expression [4]. The gene encoding SF-1, which is conserved amongst metazoans, [5,6], was called *Ftz-f1*. It encodes four different proteins ELP1, ELP2, ELP3 and SF-1 by using alternative promoters and splicing. Although ELPs are likely to play a repressive role on certain nuclear receptors, [7,8], study of mice that were selectively ablated for SF-1 has shown that it was the key activator of steroidogenic endocrine function [9].

SF-1/Ad4BP: A nuclear receptor

Nuclear receptors usually display common features such as a DNA-binding domain (DBD), a ligand binding

A

B

Figure 1
SF-1, an orphan nuclear receptor. A- Canonical nuclear receptor and SF-1 structure comparison. AF1 : activation function 1; DBD : DNA binding domain; LBD : ligand binding domain; AF2 : activation function 2. SF-1 does not harbor a classical AF-1 domain. B- SF-1 functional domains. Zn I and Zn II : zinc fingers of the DBD; Ftz-F1 : Ftz-F1 box ; NLS : nuclear localization signal ; P-rich : proline-rich region ; FP : functional region encompassing the Ftz-F1 box and the proline-rich region ; pAF : proximal activation function ; pRD : proximal repression domain ; H1 : helix I of the LBD ; dRD : distal repression domain; AF2 AH : activation function 2 activation hexamer; S203 * serine at position 203, implicated in SF-1 responsiveness to the MAPK pathway. Factors interacting with SF-1 that have allowed delineation of the functional domains are shown. Their interaction sites are figured by the grey bars.

domain (LBD) and two activation domains, amino-terminal AF-1 (activation function 1) and carboxyterminal AF-2, whose activity is normally dependent on the presence of a ligand [10] (figure 1A). In all the species studied so far, SF-1 harbors a classical DBD characterized by two Cys₂-Cys₂ zinc fingers in the N-terminal region [11]. However, as opposed to a majority of nuclear receptors, SF-1 binds DNA as a monomer, in a manner reminiscent of NGFI-B (Nur 77), ROR or LRH-1/CPF binding [10,12,13]. This binding is stabilized by an A box or Ftz-F1 box which recognizes nucleotides flanking the AGGTCA nuclear receptor core binding sequence on its 5' side (figure 1B). This protein domain defines the binding specificity of a nuclear receptor, as a function of its responsive element [12,14]. The role of A box in SF-1 activity is illustrated by a human mutation that results in sex reversal and adrenal failure [15]. Nuclear receptors usually shuttle from the cytoplasm where they bind their cognate ligands to the nucleus where they activate transcription. This shuttling is dependent on nuclear localisation signals (NLS). One NLS is present on SF-1, downstream of the DBD (amino acids 89 à 101). It is required for transcriptional activity [14]. Although SF-1 harbors a putative LBD highly conserved across species, it is classified as an orphan receptor because no *bona fide* SF-1 ligand was identified so far [16,17]. Recent experiments show that SF-1 LBD helices 1 and 12 can adopt an active conformation independently of a ligand, in response to phosphorylation of a serine residue at position 203 [18]. A conserved AF-2 domain that recruits coactivators, is present in SF-1. It is necessary but not sufficient for SF-1 transactivating activity [14,19–21]. In a majority of nuclear receptors, the AF-2 domain cooperates with the constitutive amino-terminal AF-1 domain in order to activate transcription. Such N to C interactions are essential for ligand-activated nuclear receptors function such as PPAR γ [22] or AR [23,24]. SF-1 amino-terminal region upstream of the DBD is very short and does not possess a classical AF-1. In fact SF-1 AF-2 cooperates with two activating domains downstream of the DBD. The proximal activation domain (pAF: proximal activation function) overlapping the hinge region and helix H1 of the putative LBD (amino acids 187–245) is required for maximal SF-1 activity with the coactivator SRC-1. It harbors a serine residue at 203, the phosphorylation of which is essential for SF-1 activity [18,20,25]. The FP region (amino acids 78 to 172), composed of the Ftz-F1 box and of a proline-rich region, interacts with c-jun and TFIIB for maximal activity [14].

SF-1 expression sites

As expected from its function as an essential regulator of steroidogenesis, SF-1 is expressed in the testes and ovaries as early as their anlagen appear (figure 2). In the ovary SF-1 expression rapidly decreases during development and increases after birth [26–28]. Though the placenta is a

major steroid producing tissue during pregnancy, it only shows slight SF-1 expression, detected by RT-PCR [29], but not by *in situ* hybridisation [30] nor by northern-blot [31]. Moreover, SF-1 knock-out mice do not show placental development nor placental steroid synthesis defects [29]. Ben-Zimra et al. have confirmed that SF-1 is dispensable in the placenta by showing that AP2 can substitute for SF-1 to induce P450_{scc} expression in this tissue [32]. SF-1 expression has also been detected in the pituitary anlage, in the precursors of gonadotrope cells that control reproductive function and in the ventro-medial hypothalamus (VMH) which regulates the gonadotrope axis as well as some aspects of metabolism [33–35]. At last, SF-1 has also been detected in skin [36] where it is associated to steroidogenic enzymes [37–39] and in the spleen [31,40].

SF-1 developmental expression pattern

Adrenals and gonads

SF-1 expression during development has been studied by *in situ* hybridization, immunohistochemistry and more recently with a transgenic mice line expressing the GFP reporter gene under the control of SF-1 regulatory regions.

Gonads and adrenals are derived from a common precursor, the adrenogenital primordium (AGP), located between the coelomic epithelium of the urogenital ridge and dorsal aorta. AGP is evidenced as early as 11.5 days of embryonic development in rat [28] and as early as E9 (embryonic day 9) in mouse [26] (figure 2). In mouse, adrenals and gonads anlagen progressively individualize from E9.5 to E10.5 and are perfectly distinct at E13. Primordial germ cells reach the sexually undetermined gonadal anlage by E10. After E11.5-E12, the bipotent gonad differentiates in testis (when Sry is expressed) or in ovary. Adrenal primordium is colonized at E11.5 by nerve cells that will later form the medulla. The cortex and medulla are perfectly distinct at around E16-E16.5 [26,28]. Functional zonation of the cortex is then established progressively. P450 aldosterone synthase expressing cells are found scattered throughout the cortex at E16 in rat and localize to the gland periphery by E19. Meanwhile, P450-11 β expressing cells proliferate and localize in the future zonae fasciculata and reticularis [41].

SF-1 is detected at E9 in the AGP in mouse (E11.5 in rat). At the time when gonadal and adrenal primordia individualize SF-1 is expressed in both cell populations and remains expressed at the same level throughout adrenal development. When cortex and medulla separate, SF-1 expression localizes to the cortical regions [26,28]. After E18.5 and until 6 dpp (days post partum), SF-1 is hardly detectable in mouse adrenals, and reaches foetal accumulation levels at 10 dpp [42]. This can be correlated

Figure 2
Adrenals and gonads development – SF-1 expression patterns. The key events of steroidogenic tissues development in mice are shown. Molecular players in male sex (SRY, SOX9, SF-1, Dax-1) and female sex determination (Wnt4, Dax-1) are shown. Dax-1 function in sex determination is still unclear. Abbreviations : E, embryonic day; dpc, days post coïtum ; dpp, days post partum; dpo, days post ovulation. SF-1 levels of expression are schematically presented below the time scale.

to the postnatal stress hypo-responsive period, whose biochemical basis is still unclear [43].

In the sexually undetermined gonad, SF-1 expression is high until E12.5. It disappears in the ovary until E18.5 and increases thereafter [26]. In female rat maximum accumulation is observed after 7 dpp concomitantly with increases in the number of steroidogenic theca cells [27]. In the testis, SF-1 expression remains elevated during the whole gestation and localizes in both steroidogenic Leydig cells and Sertoli cells that surround seminiferous tubules at E15 [26]. In rat testis, expression is maximal at around 7 dpp and then decreases through to adulthood when SF-1 accumulation is markedly reduced in Sertoli cells [27]. Data regarding SF-1 expression in human steroidogenic tissues are incomplete. Gonadal primordium appears in the urogenital ridge at around 32 dpo (days post ovulation), concomitantly with SF-1 expression, and

is sexually determined at 44 dpo, when SF-1 expression markedly decreases in the ovary [44,45]. Adrenal development in primates largely differs from what is observed in rodents. During the major part of *in utero* life, adrenals are composed of a large foetal zone (80 to 90% of total volume) characterized by strong outgrowth and high steroid producing capacities (mainly DHEA-S). This zone is surrounded by a transitional zone, which produces cortisol and that will later become the zona fasciculata. In turn, transitional zone is itself surrounded by the definitive zone, the embryonic equivalent to the zona glomerulosa. After birth, foetal zone regresses and the cortex acquires its definitive structure [46]. SF-1 is expressed as soon as adrenal differentiates at 33 dpc (days post coïtum), at a higher level than what is observed in undetermined gonads. SF-1 expression persists throughout foetal development and extends from foetal zone to definitive zone of the cortex [47].

Hypothalamus and pituitary

In adult mice, SF-1 is expressed in the ventro-medial hypothalamus [34,35,48,49] and in the pituitary [33]. During development, SF-1 is first expressed in the diencephalon at E12.5, and in the forming hypothalamus between E14.5 and E17 [26]. It is also expressed in the pituitary at E13.5-E14.5 where it precedes the transcripts for LH β and FSH β [33]. In adults, expression is restricted to gonadotrope cells that produce LH [33,34]. Although the VMH is implicated in the regulation of sexual functions, there is no dimorphism of SF-1 expression in this tissue in adult mice [35].

SF-1 knock-out

Gonads and adrenals

The SF-1 and ELP isoforms were knocked-out in mice by three teams simultaneously [29,34,50]. Homozygous knock-out offsprings are observed in normal proportions at birth, but die by eight days because of acute glucocorticoid and mineralocorticoid deficiency. Corticosterone concentrations are very low and correlate with a marked increase in plasma ACTH, confirming primary adrenal failure and normal function of the pituitary corticotropes, in the absence of negative feedback by glucocorticoids [9,50]. Corticosteroid injections allow survival of knock-out mice [9]. Homozygous knock-outs also show female external genitalia, regardless of their genetic sex. Internal observation of SF-1 ablated mice shows a complete lack of adrenal glands and gonads and a persistence of Müllerian ducts, regardless of the genetic sex [29,50]. Absence of testes in homozygous mutant male mice precludes MIS (müllerian inhibiting substance) and androgen production, which probably accounts for the observed phenotypes. It is noteworthy that the abnormalities observed at birth are not observed during precocious development. Indeed, at E10.5, when sex determination has not yet occurred, the bipotential gonad is normal and colonized by primordial germ cells in knock-out animals. However at E12-E12.5, when sex determination normally occurs, mutant mice gonads regress by apoptosis. The adrenal primordium also forms and progressively regresses at E11.5 [50]. Selective ablation of SF-1 but not of the ELP1-3 transcripts resulted in the same phenotypes, demonstrating the essential role of SF-1 in their etiology [9].

Altogether, these results show that SF-1 is indeed required for differentiation and maintenance of the primordia for adrenals and gonads, but that its presence is not required for their early formation. The mechanisms underlying the complete degeneration of the primordia are largely unknown.

VMH and pituitary

SF-1 is normally expressed in the VMH and pituitary. The histological appearance and physiology of both tissues

have been studied in knock-out animals. SF-1 $-/-$ adult mice neither express LH β nor FSH β , two markers of pituitary gonadotrope cells, and do not show the characteristic structures of the VMH [33–35,51,52]. These are present at E17 but progressively regress thereafter, an observation reminiscent of the situation in the gonads and adrenals [35]. The cause of the absence of gonadotropins in gonadotrope cells is not clear. Absence of GnRH in SF-1 $-/-$ mice is not probable, as hypothalamic GnRH-producing neurons are present and normally deliver it to the medial eminence of the pituitary [35,53]. Pituitary-specific ablation of SF-1 confirms the pituitary origin of the absence of gonadotropins. Indeed these animals show the same gonadotrope defects though their VMH is perfectly normal [53–55]. A direct effect of SF-1 in the pituitary is thus probable, especially when considering that it is able to control the in vitro expression of LH, FSH and GnRH receptor [56–63]. However, although GnRH receptor is not detected in knock-out mice [33,53], supra-physiologic doses of GnRH are able to induce LH and FSH expression through an unknown SF-1-independent mechanism [35,53].

Primary consequences of SF-1 ablation at the level of pituitary and hypothalamus have secondary consequences in their target organs. Indeed, pituitary-specific knock-out mice show marked hypogonadism which is characterized by a 95% decrease in male and female gonad mass and absence of sexual maturation, resulting in sterility [35,53,54]. However, hypoplastic gonads have normal morphology of immature gonads, indicating that their precocious determination and differentiation normally occur. This phenotype, which is equivalent to the phenotype of gonadotropes-ablated mice [64], can be reversed by PMSG injection, indicating that this is indeed gonadotropins absence which is responsible for gonadal hypoplasia in pituitary-specific knock-outs [53]. This is confirmed by observation of an attenuated gonadal phenotype in mice with a pituitary-specific SF-1 hypomorphic allele [55].

Lesions of the ventro-medial hypothalamus obtained by stereotaxic surgery induce hyperphagia and obesity, suggesting that the VMH could participate to satiety and feeding control [65]. It is noteworthy that SF-1 $-/-$ mice that are maintained by adrenal transplantation, develop marked obesity after 8 weeks. Around 6 months, their body mass is nearly twice as wild type and this is correlated to a marked increase in adipose tissue. Although the molecular basis for such a phenotype is not known, obesity seems to be correlated to a decrease in daily exercise observed as early as 7 weeks [52]. These results confirm that the VMH may be implicated in the etiology of certain obesity phenomena, and suggest that SF-1 may have broader roles in metabolism control.

Collectively, these data indicate that SF-1 is required for the differentiation of gonadotrope cells of the pituitary and of the ventro-medial hypothalamus. Its presence does not seem to be required for formation of the VMH of which the anlage is present in knock-out mice, but may participate to its maintenance during development.

Spleen

The discovery that SF-1 is expressed in the spleen raises the question of its potential role in non-steroidogenic peripheral tissues. SF-1 ablation induces defects in the establishment of splenic vascularization as well as defects in erythropoiesis, although most hematopoietic cell lines are correctly matured and differentiated [40]. Whether SF-1 could be implicated in the vascularization of other tissues such as the adrenals or gonads is an interesting question. A defect in the formation of the endothelium could at least in part, be responsible for the involution of gonadal and adrenal primordia in knock-out mice. It is noteworthy that a steroidogenic tissue-specific endothelial growth factor - EG-VEGF - has recently been identified [66]. A potential implication of SF-1 in EG-VEGF or EG-VEGF receptor expression has not been studied so far.

Human mutations of SF-1 : A comparison with murine phenotypes

Three SF-1 mutations have been described in humans so far. Heterozygous G35E mutation which is located in the first zinc finger of the DBD induces complete sex reversal of the 46XY affected individual, which is associated to major adrenal insufficiency [67]. Heterozygous R255L mutation, located in the hinge region, induces bilateral adrenal agenesis, but does not impair ovarian development of the 46XX patient [68]. Homozygous R92Q mutation which alters the A box of SF-1 is responsible for right adrenal agenesis, left adrenal hypoplasia and sex reversal. Both the parents and sister of the affected individual are heterozygous for the mutation and do not show striking phenotypes [15]. All these mutations affect SF-1 binding and transactivating capacities without altering its accumulation. Mutations that result in a phenotype when heterozygous, completely abrogate SF-1 transactivating capacity in cell transfection [67,68]. As the resulting proteins have no dominant-negative effect, the drastic phenotypes observed in heterozygotes, suggest that SF-1 works as a dosage-sensitive protein *in vivo* [67,68]. This is consistent with the absence of phenotype of heterozygotes bearing the R92Q mutation which only slightly alters SF-1 transactivating properties *in vitro* [15]. These results prompted investigators to study the effects of SF-1 haploinsufficiency in mice. Although not as obvious as in humans, heterozygous SF-1 knock-out results in adrenal hypoplasia in both male and female mice at E15.5. After birth, adrenal hypoplasia is associated to zona fasciculata hypertrophy as well as a marked decrease in corticosterone

response to stress or feeding, although basal corticosterone is unchanged. It's noteworthy that conserved basal levels are correlated to increased StAR and MC2R transcripts, indicating that factors other than SF-1 can regulate StAR and MC2R transcription, at least in haploinsufficient mice [69]. Collectively, these results show that SF-1 acts as a dosage-sensitive factor for the proper differentiation and function of the adrenal cortex in both mouse and human.

It is more difficult to put together human and murine gonadal phenotypes resulting from SF-1 mutation. Mutant 46XY heterozygous (G35E) or homozygous (R92Q) individuals show complete sex reversal characterized by poorly differentiated hypoplastic gonads and Müllerian duct persistence [15,67]. These observations confirm the essential role of SF-1 for testes differentiation and Müllerian duct regression. On the contrary, a 46XX heterozygous woman bearing the R255L mutation does not show significant ovarian dysfunction. The heterozygous state of the mutation may account for the absence of ovarian phenotype. However, the complete adrenal agenesis observed in this patient argues against such an explanation [68]. LRH-1 is a close homologue to SF-1 which is overexpressed in the liver where it participates to bile acids synthesis control by binding to SFRE-like sequences [70]. It is important to consider that LRH-1 is highly expressed in the ovaries of humans and rodents where it may control the promoter activity of steroid hydroxylase genes [71–73] and to a much lesser extent in the adrenal cortex [42,73]. The high level of LRH-1 expression in the ovaries may thus account for redundancy, masking the effect of SF-1 mutation. However, as heterozygous SF-1 mutant mice show non-characterized ovarian hypoplasia, species-specific mechanisms in ovarian differentiation may be envisaged [69]. Though, one must keep in mind that SF-1 null mice do not express SF-1 protein whereas human patients still express the mutant version that may contribute to the displacement of subtle equilibriums. At last, another possible explanation is that pituitary gonadotrope function is not affected in humans whereas it is abolished in mice. The strong ovarian phenotype in mice would then result from a combination of central and primary defects. Gonad-specific SF-1 knock-out may provide important information regarding this issue.

Despite interspecies differences, observations in SF-1 null mice and human mutants clearly show a key role for SF-1 in the development and / or differentiation of steroidogenic tissues and their central regulators (hypothalamus and pituitary) (table 1). Tissue and cell-specific SF-1 knock-outs should be valuable models to differentiate between primary effects of SF-1 ablation in steroidogenic tissues and effects resulting from central nervous system defects.

Table 1: Phenotypes resulting from genetic ablation or mutations of the orphan nuclear receptor SF-1.

Organism	Mouse		Human
Genotype	SF-1 -/-	SF-1 +/-	SF-1 m/+ ou SF-1 m/m
Adrenal	- Agenesis	- Histological defects - Hyporesponse to stress - Compensatory growth defects	- Insufficiency (agenesis or dysgenesis)
Testis	- Agenesis - Sex reversal		- Sex reversal
Ovary	- Agenesis		- Normal
VMH	- Agenesis - Obesity caused by absence of the VMH (8 weeks)		
Pituitary	- Defects of gonadotrope cells		

A role for SF-1 in cell differentiation and proliferation?

All the data presented above do not allow to distinguish between SF-1 implication in cell fate determination / differentiation and proliferative effects. ES cells stably expressing SF-1 are able to morphologically differentiate into steroidogenic cells that express the rate-limiting P450_{scc} enzyme. P450_{scc} expression and subsequent progesterone production are stimulated by cAMP. This activation is prevented by cycloheximide, indicating that it requires de novo synthesis of factors that are absent from unstimulated cells. At last, P450_{scc} induction is independent of SF-1 transactivating properties as measured by activation of a reporter gene, under the control of a SF-1 responsive element. This suggests that SF-1 is required for differentiation of ES cells and for the expression of factors that are implicated in cAMP responsiveness, although it doesn't directly participate in the latter [74].

After unilateral adrenalectomy, the remaining adrenal is able to compensate for adrenal defect by engaging in hypertrophy and hyperplasia (compensatory growth), through a regulatory loop implicating the VMH. Beuschlein et al. have shown that in SF-1 +/- mice, there was no compensatory growth in the remaining adrenal following unilateral adrenalectomy, indicating that SF-1 was probably required for hyperplasia and hypertrophy to occur [75]. This phenotype is correlated to absence of overexpression of AsP, an adrenal-specific protease which cleaves pro- γ -melanotropin into an adrenal mitogenic peptide [76], and of PCNA, a cell proliferation marker [77], in response to unilateral adrenalectomy. This shows that beyond its role in cell differentiation, SF-1 may also be crucial for cell proliferation in steroidogenic tissues.

SF-1 target genes*Genes implicated in steroidogenesis*

SF-1 was initially identified for its capacity to interact with and activate the promoters of the steroidogenic enzymes P450_{SCC}, CYP11B1 and CYP21 [1,2], through the con-

sensus AGGTCA sequence. In the last ten years, transient transfection studies have shown that SF-1 participates to the expression of all steroidogenic enzymes in the adrenal cortex and gonads (table 2). In any case except for CYP11B2 which synthesizes aldosterone in the zona glomerulosa [78], SF-1 activates basal expression of these genes. Because of its tissue-restricted pattern of expression, SF-1 is obviously a key factor in the tissue-restricted expression of steroidogenic enzymes. Its implication in their cAMP responsiveness is still a subject of debate. At least, cAMP-sensitive promoter regions often overlap with SF-1 responsive elements the mutation of which alters cAMP responsiveness [47,78–86]. These experiments indicate that SF-1 may be required to mediate cAMP responsiveness, but they do not show that it is sufficient for this process. Indeed, inside P450_{scc} promoter, a proximal SF-1 responsive element (-40) is solely required for basal activity, whereas a distal site (-1600) is required for hormonal sensitivity *in vivo* [79]. If SF-1, was intrinsically a mediator of cAMP signaling, it would be difficult to understand how it would behave differently from one site to another. This underlines the essential role of the DNA context of the SF-1 responsive element in its ability to transduce activation of the cAMP pathway to promoters.

Besides steroidogenic genes, SF-1 is also able to modulate cholesterol delivery to steroidogenic reactions, by controlling expression of the HDL-receptor SR-BI, of intracellular cholesterol transporter SCP2 [87], and of StAR which transfers cholesterol from the outer to the inner mitochondrial membrane [88]. SF-1 can also stimulate *de novo* cholesterol synthesis in steroidogenic tissues through activation of HMG-CoA synthase, irrespective of intracellular cholesterol concentrations [89]. SF-1 also controls expression of the receptors for ACTH and FSH, the hormones that stimulate adrenal and gonadal steroidogenesis, respectively. Our group has also demonstrated that SF-1 could also control *akr1-b7* expression *in vitro* and *in vivo*. This gene whose expression is controlled by ACTH in the

Table 2: A summary of SF-1 target genes. (After Hammer and Ingraham, Ref. [11], updated) The cell types where the studies were conducted are presented. Studies in vivo using transgenic approaches are specified. Basal: SF-1 is required for basal promoter activity of the gene being studied. Induction: SF-1 participates to the cAMP responsiveness of the gene. A different induction signal is stated. N.D. SF-1 implication in the cAMP responsiveness was not determined. Lower case letters before the names of the promoters correspond to the species that were studied (h: human; r: rat; b: bovine; m: mouse).

Gene promoter	Cell type /Transgenic technique	Basal activity/induction by cAMP	Bibliography
hP450scc	Additive transgenesis, H-295	basal + induction	[79,80]
rP450scc	MA-10, rat granulosa	basal	[138,188]
bP450scc	Y1, bovine luteal cells, COS1	basal + induction	[162]
h3β-HSD type II	H295, HeLa	basal + N.D.	[189]
mCYP21	Y1	basal + N.D.	[2,190]
hCYP11B1	Y1, H295	basal + induction	[78,81]
bCYP11B1	Y1, I-10 (Leydig)	basal + induction.	[191,192]
hCYP17	H295	basal + induction	[47,82,183,185]
bCYP17	Y1, COS-1	basal + induction	[83,84]
rCYP19	R2C, H450, Y1	basal + induction	[86,164,193,194]
hCYP19	Bovine luteal cells	basal + induction	[85]
h/mCYP11B2	H295	inhibition by SF-1	[78]
AKR1-B7	Additive transgenesis, HeLa, CV-1	basal	[42,90–92]
HDL-R/SR-BI	Y1, HTB9	basal + induction	[195–198]
SCP2	Y1, HTB9	basal + induction	[199]
hStAR	Y1, BeWo, H295	basal + induction	[200–203]
mStAR	Y1, MA-10	basal	[112]
rStAR	Y1, HTB9 (human bladder carcinoma)	basal + induction	[204]
bStAR	HeLa	basal + induction	[205]
HMG-CoA reductase	CV-1, MA-10	basal + N.D.	[89]
hMC2R	H295-R	basal + induction	[206,207]
mMC2R	Y1	basal + N.D.	[208]
mFSH-R	HEK-293	basal	[60]
rFSH-R	JEG-3	basal + inhibition of PKA induction	[209]
rLH-R	Granulosa	basal inhibition	[210]
R-GNRH	αT3-1	basal	[61,62,211,212]
LHβ	Additive transgenesis, LβT2, αT3-1,	basal + induction by GnRH in association with Sp1, EGR-1 and Ptx1	[58,156,157,213,214]
hαGSU	LβT2 gonadotropes	basal + induction by GnRH	[215]
Neuronal mNOS	αT3-1, NIH3T3	basal	[96]
b-ocytocin	TM4	basal	[216,217]
PRL-R	MLTC (Leydig)	basal	[218]
MIS	Knock-in mice, HeLa, JEG-3	basal	[104,107,108]
DAX-1	Additive transgenesis, H295, JEG-3	basal	[187,219–221]
RLF/INSL3	MA-10, HeLa, mLTC-1, HEK293	basal	[109,110]
α-inhibin	tsa, GRMO2 granulosa	basal + induction	[163]

adrenal cortex, encodes a protein which detoxifies isocaproaldehyde, produced by the cleavage of cholesterol through action of P450scc [42,90–93]. It is noteworthy that a new class of genes coding proteins able to reduce toxic side-effects of steroidogenic reactions, is emerging. Indeed, expression of superoxide-dismutase 2 (SOD2), which protects adrenal cells against free radicals generated during steroidogenesis, is also controlled by ACTH [94]. However Chinn and colleagues have not studied the role of SF-1 in the control of SOD2 expression in adrenocortical cells. Altogether, these results confirm the major role of SF-1 as a key activator of steroidogenesis. However, most of these studies rely upon transient transfections in heterologous cells that do not necessarily represent a good

model enough for studying the role of SF-1 on gene transcription. As SF-1 null mice completely lack steroidogenic tissues, the easiest alternative to study these mechanisms in a physiological context, is to generate transgenic mice harboring wild-type or mutant constructs of the promoter being studied.

Genes of the central nervous system

Analyses of SF-1 null mice have shown the key role of this factor for the establishment of the hypothalamus-pituitary-adrenal and hypothalamus-pituitary-gonadal axes. Neuronal NO synthase participates to the secretion of GnRH, the neuropeptide responsible for the synthesis and secretion of LH and FSH by pituitary [95]. Although SF-1

knock-out mice do not show obvious GnRH secretion defect [35,53], SF-1 is able to control neuronal NO synthase gene transcription *in vitro* [96]. This raises the question of a more general role of NO in the etiology of the phenotypes in null mice. Pituitary glycoproteins LH and FSH are composed of a common subunit, α GSU, which is associated to a β chain, specific to LH or FSH. Gonadotropins production and secretion is controlled by GnRH which activates Ca^{2+} and PKC pathways through its receptor [97]. *In vitro*, SF-1 controls expression of the GnRH receptor, α GSU and LH β , but not of FSH β . All these proteins are absent from SF-1 $-/-$ mice pituitaries suggesting that SF-1 participates to their expression *in vivo* [53,54]. However, null mice treatment with supra-physiological GnRH doses induces LH and FSH expression in the absence of detectable amounts of GnRH receptor [35,53]. Although the question of GnRH action in SF-1 null mice is as yet unresolved, these surprising results shed light on transcription factors other than SF-1, that may participate to LH and FSH expression *in vivo*.

Genes implicated in sexual differentiation and sex determination

In mammals, male sex determination is triggered by the Y chromosome-borne SRY gene. SRY activation in turn triggers expression of SOX9 which stimulates MIS transcription in Sertoli cells. This hormone from the TGF- β family, is responsible for the regression of Müllerian ducts that normally form oviducts, uterus and the upper third of the vagina in females [98].

SF-1 expression in the urogenital ridge at E9.0 [26] precedes expression of SRY in pre-sertoli cells at E10.5 in mouse [99,100]. SF-1 has recently been shown to regulate human and porcine SRY expression. One SF-1 responsive site at -327 is required for a modest activation of human SRY promoter [101] whereas two sites are essential for porcine SRY promoter activity in porcine genital ridge cells [102]. Although the physiological relevance of such an observation is not established yet, treatment of NT2/D1 embryonic carcinoma cells with cAMP induces SF-1 phosphorylation that prevents its binding to the SRY promoter, thus downregulating human SRY expression [101]. Nonetheless, it is noteworthy that residual SRY expression is observed in SF-1 knock-out mice [103], suggesting that SF-1 may not be essential for triggering SRY expression.

SF-1 and MIS are coexpressed in developing Sertoli cells [104], and SF-1, in association with SOX9 [105], GATA-4 [106] and WT-1 [107] is able to stimulate MIS promoter activity in transient transfections (figure 3). Male SF-1 null mice show Müllerian duct persistence [29,34,50]. However, the absence of gonads in these animals does not allow a conclusion on a direct effect of SF-1 to be drawn. This difficulty was overcome by mutating the proximal SF-1 responsive element of the MIS promoter by homolo-

gous recombination with the endogenous MIS locus. This mutation reduces MIS accumulation albeit to an extent which is insufficient to prevent Müllerian duct regression, whereas when the SOX9 binding site is mutated by the same procedure, there is Müllerian duct persistence in male mice (figure 3). These results suggest that SOX9 triggers MIS expression whereas SF-1 acts as a quantitative regulator [108].

Gonadal descent is a process associated to male sexual differentiation which is dependent on regression of the cranial suspensory ligament and proliferation of the gubernaculum specifically in males. The knock-out of the *Ins13/RLF* gene, which codes a protein produced by Leydig cells, results in a defect in testes descent. It is noteworthy that SF-1, at least *in vitro*, is able to control RLF expression through three responsive-elements [109,110]. Confirmation of the role of SF-1 in testis descent via RLF should come from observation of testes position in SF-1 $+/-$ mice, or of gubernaculum proliferation in null mice.

SF-1 target genes : unanswered questions

The number of SF-1 potential target genes is rapidly growing. However few studies are based on the *in vivo* demonstration that SF-1 responsive elements are indeed required for putative target genes expression. Analysis of putative target genes in SF-1 haplo-insufficient mice may confirm the role of SF-1 in their expression. However, compensatory mechanisms as those observed for StAR expression in SF-1 $+/-$ mice, may mask the effects of SF-1 dosage reduction [69].

The presence of gonadal and adrenal anlagen in SF-1 knock-out mice and their rapid disappearance during development suggests that SF-1 regulates genes that are implicated in cell survival and/or proliferation. The majority of known SF-1 target genes is responsible for the maintenance of differentiated function rather than survival of steroidogenic tissues. Degeneration of steroidogenic tissues in null-mice is due to apoptosis [50]. It was recently shown that glucocorticoids can protect glandular tissues such as ovarian follicular cells against apoptosis although they have a pro-apoptotic effect on hematopoietic cells [111]. As SF-1 controls the expression of StAR [112] and P450_{scc} [79], two enzymes that are indispensable for glucocorticoids production, apoptosis in SF-1 null-mice may be due to glucocorticoids defects. In fact, this is rather unlikely because StAR [113] or P450_{scc} [114] genetic ablation results in histological defects of the adrenals that are linked to progressive cholesterol accumulation, but does not result in adrenal regression during development.

POMC is the pituitary peptide that is cleaved to produce ACTH, pro- γ -MSH and β -LPH. Interestingly, POMC

Figure 3

MIS promoter. Binding sites for the transcription factors required for proper MIS expression are shown. Their position in human MIS promoter is indicated (hMIS). WT1 and Dax-1 are able to respectively stimulate or repress MIS promoter activity by interacting with SF-1 bound to its proximal responsive element. Effect of the mutation of the proximal SFRE or SOX9 responsive element introduced by knock-in in mice on Müllerian ducts regression is indicated. Abbreviations : Sox BS, SOX factors binding site; SFRE, SF-1 responsive element.

knock-out mice show defective adrenal development [115]. The role of ACTH in trophic and mitogenic stimulation of the adrenal cortex is still a subject of intense debate [76,116,117]. The N-POMC(1-52) peptide, derived by cleavage of pro- γ -MSH shows highly mitogenic activity on adrenocortical cells. AsP, the adrenal-specific protease which is responsible for its cleavage, and its cognate receptor have been cloned recently. These are specifically expressed in the outermost regions of the cortex and the protease is required for Y1 cells growth [76,118]. An important question is now to determine whether SF-1 regulates AsP and its receptor expression in the adrenal cortex.

Control of SF-1 expression and activity

SF-1 activity on its target genes must be tightly controlled. This can be achieved by ligands or cofactors (coactivators/corepressors or transcription factors) or directly by modulating expression of the nuclear receptor. In numerous steroidogenic genes promoters, cAMP-responsive regions overlap with SF-1 responsive elements. This chapter will particularly address the complex issue of cAMP signalling transduction through SF-1.

SF-1: still an orphan?

During the last decade, numerous orphan nuclear receptors have been cloned without any known ligand. Some, like LXR, FXR, PXR or CAR, have since been attributed a ligand, whereas others like Nur77/NGFI-B, Nurrl-1, LRH-1 or DAX-1, have no known ligand so far and seem to be activated by other mechanisms [5,10]. 25-hydroxycholesterol, an hydroxylated cholesterol derivative is able to activate CYP21 promoter transcription in a SF-1 dependent manner in heterologous CV-1 cells, indicating that it could be a SF-1 endogenous ligand [119]. Nonetheless, in steroidogenic MA-10 cells that naturally express SF-1, both exogenous and endogenous 25-hydroxycholesterol are unable to stimulate endogenous P450_{scc} expression as well as six SF-1-responsive reporter genes [16]. Collectively, these results tend to prove that 25-hydroxycholesterol is not a bona fide ligand for SF-1 in steroidogenic cells. This is confirmed by the ability of SF-1 LBD to adopt an active conformation independently of any ligand [18].

Factors controlling SF-1 transcription

A small 90 bp SF-1 proximal promoter is specifically expressed in adrenocortical cells in transient transfections. This region encompasses an E-box (-87/-82), a Sp1 binding site (-30/-24) and a CAT box that binds CBF (-68/-59) [120,121] (figure 4). If the role of the latter is not

clearly demonstrated, transcriptional control of SF-1 expression at least requires the E-box which is conserved in human and which is functional in both steroidogenic and non-steroidogenic cells [120,122–124]. This element is able to bind the ubiquitous USF factor contained within pituitary α T3-1 cells, steroidogenic Y1 and JEG-3 cells, as well as CV1 and HeLa cells [123]. None of these interactions however, can account for tissue-restricted SF-1 expression. SF-1 itself is able to bind a site which is present in its own first intron in rat and human genes (+156/+163) [124,125] (figure 4). Whereas Nomura et al., [125] have shown the role of this sequence for the expression of a reporter gene in Y1 cells, or in response to SF-1 overexpression in heterologous CV-1 cells, Woodson et al., using the rat gene and Oba et al., using the human gene, were unable to obtain the same results in either steroidogenic or non-steroidogenic cells [120,124]. However, it is worth considering that some sequences contained within the first intron might be required for SF-1 expression, though their specificity is not yet established [124]. This is confirmed by the use of different lengths of SF-1 regulatory regions and intragenic sequences in transgenic mice [49,126]. SF-1 is expressed in the urogenital ridge as early as E9.5 at similar levels in males and females. When sex determination occurs between E10.5 and E12.5, SF-1 expression strongly decreases in the ovary until E18.5, whereas it remains elevated in the testis. After birth, expression rises in the ovary although it is reduced in adult testis [26,27]. Pod-1/Capsulin is a transcription factor of the b-HLH family which is able to heterodimerize with other factors of the family by binding to E-boxes (figure 4). It participates to kidney and lung differentiation [127] and displays a sexually dimorphic pattern of expression in the gonad, which is reminiscent of SF-1 gonadal expression. However, Pod-1 is expressed in gonadal regions where SF-1 is not expressed (*i.e.* coelomic epithelial cells, peritubular myoid cells and epithelial-like cells). In fact, it seems that Pod-1 may act as a repressor of SF-1 promoter activity through interaction with the previously described E-box [128]. Sox9 and SF-1 are colocalized in somatic cells of the testis and follow parallel expression patterns during development [129]. They both participate to transcriptional activation of the MIS promoter in males [105]. Recent results show that Sox9 is able to induce SF-1 expression in heterologous cells and that a Sox9 binding site (-110/-104) is required for SF-1 expression in Sertoli and Y1 cells [130] (figure 4). GATA-4 is also dimorphically expressed in the gonad. Whereas its expression is high in the undetermined gonad it decreases as ovary differentiation starts, although it is maintained in the testis. This dimorphism may participate to the control of MIS expression [131], but GATA-4 is also able to moderately activate SF-1 expression via a conserved site at -177/-172 (figure 4). This activation is dependent on the cell type and seems to be essentially restricted to Sertoli cells where

SF-1 participates to MIS expression [132]. Although most elements required for SF-1 expression in steroidogenic tissues are likely to be localized in the 5' flanking regions and first intron of the gene, a GFP/SF-1 fusion, the expression of which is directed by a 50 kb BAC comprised of SF-1 promoter, first exon and first intron, is not expressed in pituitary gonadotropes [49]. Although a single transgenic line was studied so far, this indicates that further downstream sequences might be required for pituitary expression. However, there is no mention of pituitary expression in the work of Zubair et al., who used SF-1 regulatory regions extending from the first intron to the seventh exon [126]. Altogether, these data allow a better understanding of SF-1 tissue-specific expression especially in the gonads but do not establish a link between SF-1 transcription and the cAMP signalling pathway.

Is SF-1 accumulation altered by cAMP pathway stimulations?

In vivo, SF-1 protein accumulation in the adrenals and gonads is unchanged by a four weeks hypophysectomy in rats [133]. However an eighty hours treatment of mice with dexamethasone, induces a marked reduction of SF-1 mRNA accumulation in the adrenals [134], suggesting that compensatory mechanisms may have masked the effects of long term hypophysectomy on SF-1 accumulation. Nonetheless, lipopolysaccharide treatment which induces increases in circulating ACTH concentrations, has no effect on SF-1 accumulation [134]. The problem is far more complex in cell culture systems. Whereas numerous papers show that SF-1 mRNA accumulation is unchanged in Y1, MA-10, theca or bovine granulosa cells in response to forskolin or PKA catalytic subunit overexpression [135–138], one paper describes a slight increase in bovine adrenocortical cells treated with ACTH [139]. At last, in human granulosa cells [140] or in forskolin-treated Y1 cells, SF-1 protein accumulation increases independently of an increase in its mRNA accumulation [137]. Based on this observation, Aesoy et al. have proposed a post-translational model in which PKA could stabilize SF-1 protein [137]. However, this was only demonstrated in a heterologous cell system overexpressing both SF-1 and the PKA catalytic subunit. Interestingly, we have not been able to obtain similar results with both Y1 and ATC-1 [141] adrenocortical cell cultures treated with forskolin or ACTH, respectively. Our unpublished data rather suggest that SF-1 accumulates into cell nucleus in response to cAMP, without a concomitant increase in overall protein accumulation (Bruno Ragazzon, personal communication). This increase in SF-1 nuclear accumulation correlates with increased SF-1 binding in gel shift experiments (Christelle Aigueperse, personal communication). Whatever the changes in SF-1 expression may be, simple modulations of SF-1 accumulation are unlikely to account for some SFREs being implicated in cAMP-responsiveness while others only support basal promoter activity *in vivo*

Figure 4

Schematic representation of SF-1 regulatory regions. A summary of the experimental results obtained with SF-1 regulatory regions in humans, rats and mice is presented. Cis elements are conserved across the three species. Numbering may vary from one species to another. Pod-1/Capsulin and USF bind to the same response element. USF activates SF-1 transcription whereas Pod-1 is likely to repress it. Abbreviations : GATA, GATA proteins response element; Sox BS, Sox proteins binding site; CAT, CAAT box; Sp1, Sp1 response element; Inr, initiator; SFRE, SF-1 responsive element; USF, upstream stimulatory factor; CBF, CAT box binding factor.

[42,79]. This differential activity may be achieved by more subtle mechanisms that control SF-1 activity, such as interaction with other transcription factors and / or cofactors.

SF-1 cofactors

Ligand-dependent nuclear receptors activate their target genes transcription through interactions with coactivators and/ or corepressors that link receptors to the transcription machinery. Accordingly, SF-1 harbors an AF2 activation domain in its LBD (figure 1B). This motif (LLIEML, consensus LXXLL) is necessary but not sufficient for transactivation [14,19–21] which also depends on two amino-terminal regions of the protein, the FP region [14] and a proximal activation domain [20,25]. SF-1 proteins bearing mutations in their AF2 domain have dominant negative properties on CYP17 promoter activation by PKA in Y1 cells. This suggests that SF-1 AF2 is implicated in the transduction of the cAMP signal [83]. As ligand-activated nuclear receptors, SF-1 interacts with numerous coactivators such as SRC1 [19,20], RIP140 [142], PNRC and PNRC2 [143,144], hMBF1 [145], TIF2 [25], p/CIP [146] and GCN5 [147]. These interactions, independent of an exogenous ligand, are dependent on AF-2 and for some of them, on proximal interaction domain integrity. Most of these interactions are mediated by LXXLL motifs found on coactivators. PNRC and PNRC2 are quite unique in that they interact with SF-1 and other nuclear receptors through SH3 proline-rich motifs [143,144]. None of these coactivators is specific for SF-1 and none of them shows a steroidogenic tissue-restricted pattern of expression. Nonetheless, two of them may be required for integration

of the cAMP signalling (figure 5). TIF2 and p/CIP interact with SF-1 through the AF-2 and proximal activation domain [25,146]. Overexpression of TIF2 or p/CIP in heterologous or Y1 cells, stimulates transcription of a reporter gene driven by four copies of a SF-1 responsive-sequence of the bovine CYP17 promoter. However, whereas p/CIP increases sensitivity to PKA overexpression in the presence of SF-1, overexpression of the catalytic subunit of the PKA inhibits potentiation of SF-1 activity by TIF2, through a decrease in TIF2 protein accumulation [146]. In a more physiological system, one might imagine that on the sites where it participates to cAMP-responsiveness, SF-1 would preferentially associate to p/CIP, whereas where it participates to basal promoter activity, SF-1 would rather associate to TIF2. What could allow SF-1 to choose between those two coactivators? Although the sequence of the SF-1 responsive element may participate to this choice, it is possible that adjacent transcription factors, endowed with cAMP sensing capacity, may modulate cofactors recruitment by SF-1. This would allow modulation of SF-1 activity in response to extra-cellular signals.

DP103 is a DEAD-box protein which is highly expressed in steroidogenic tissues (table 3). Although it has intrinsic RNA helicase properties as other proteins of its family [148], DP103 physically interacts with SF-1 through a newly described repressive domain, located in the vicinity of the proximal activation domain [149]. DP103 harbors a C-terminal repression domain that by itself, represses SF-1 activity. DP103 repressive function is independent of its helicase activity and can decrease P450scc and P450c21

Figure 5

Presumed effect of the coactivators p/CIP and TIF2 on SF-1 transactivation. (After Borud et al., Ref. [188]). In the absence of PKA, p/CIP and TIF2 potentiate SF-1 transcriptional activity. When SF-1 is associated to p/CIP, overexpression of PKA induces a marked increase in SF-1 transcriptional activity. On the contrary, PKA overexpression prevents TIF2-dependent potentiation of SF-1 activity. The decrease of TIF2 protein accumulation caused by PKA overexpression may explain these observations. SFRE : SF-1 responsive element.

promoter activity, inducing a significant reduction in progesterone production by Y1 cells [148]. One interesting question is now to analyze whether DP103 is implicated in the cAMP responsiveness of steroidogenic enzymes genes.

Transcription factors associated with SF-1

Apart from interaction with *bona fide* cofactors, SF-1 also interacts with numerous transcription factors (table 3) that modulate its activity either by binding to adjacent DNA sequences or by interacting with SF-1 without bind-

ing to DNA [106,107,150–152]. The regions of interaction between SF-1 and other transcription factors are rather broadly delineated. These can overlap with previously described regions such as AF-2 or the proximal activation domain [14,160] but also extend to the DBD [107,153] and LBD [107,154] or distal [152] and proximal [148] repression domains. These interactions result in variable responses depending on the promoter or cell type under experiment.

Table 3: Transcription factors or cofactors that interact with SF-1. For each interacting factor, the resulting functional interaction, the experimental approach used to evidence the physical interaction and the model promoter are indicated.

Factor	Functional interaction	Physical interaction	Promoter	Bibliography
TreP132	allows CBP/p300 recruitment	Co-IP, pull-down, two-hybrid	P450scc	[160,161]
GATA-4	Independent of GATA binding to DNA	Pull-down	MIS	[106,150]
SOX9	Increases transcription in the presence of SF-1	Two-hybrid, pull-down, co-IP, EMSA	MIS	[105]
WT1-KTS	Activation by WT-1 is dependent on SF-1 binding to its site. No WT-1 binding to DNA	Two-hybrid, GST pull-down	MIS	[107]
Sp1	Cooperation dependent on the cell type	Co-IP, two-hybrid, EMSA	StAR	[202]
Sp1	Cooperation required for basal and cAMP-induced activity. Allows recruitment of CBP	Two-hybrid, EMSA	bovine P450scc	[153,162]
Egr-1	Synergistic activation. Egr-1 expression is induced by GnRH.	Pull-down	LH- β	[155-157]
Ptx-1	Synergy depends on SF-1 binding to DNA	Pull-down, two-hybrid	LH- β	[158,159]
CREB	Synergy in basal and cAMP-induced conditions. Allows CBP recruitment	Pull-down	α -Inhibin	[163]
CREB	Synergy in response to cAMP. FSH induces CREB and SF-1 phosphorylation	Not demonstrated	Aromatase	[86,164]
AP-1/c-jun	Synergy for P450scc and an artificial promoter activation	Pull-down	P450scc and SFRE-tk-CAT	[14,21]
TF-IIB	No determined	Pull-down		[14]
C/EBP β	C/EBP binding sites are required for activation by SF-1	Pull-down	mStAR	[112]
USF	USF is required for SF-1 to activate rFSH-R promoter. Activation is inhibited by PKA.	Not demonstrated	rFSH-R	[209]
AR	AR represses LH β transcription by interacting with SF-1	Pull-down	bLH β	[154]
DPI03	Inhibits SF-1 transcriptional activity by interacting with a proximal repression domain.	Co-IP, pull-down	P450scc, P450c21, progesterone production	[148,149]
P54 ^{nrb} et PSF	Repression of basal and induced hCYP17 promoter activity	EMSA, co-IP	hCYP17	[222]
WT1	Aromatase transcription inhibition. Integrity of the SFRE is required	Not demonstrated	Aromatase	[223]
DAX-1	Inhibits SF-1 transcriptional activity NCoR/Alien recruitment	Pull-down, two-hybrid	Synthetic promoters and SF-1 target genes	[107,151,152]

A first class of factors, illustrated by the studies on MIS and LH- β promoters, encompasses proteins that will restrict SF-1 target genes expression in a very narrow region of the organism in a particular context. Indeed, the combinatory interactions between SF-1, WT-1 [107], GATA-4 [106,150], SOX-9 [105,108] and DAX-1 [107] allow MIS expression specifically by Sertoli cells of the male gonad, just before regression of the Müllerian ducts (figure 3). Also, this is an interaction between Egr-1, Ptx1 and SF-1 that allows expression of the LH- β subunit in pituitary gonadotrope cells in response to GnRH stimulation [155-159].

Another group of factors is more implicated in SF-1 target genes response to external stimuli. Indeed, SF-1 interaction with TreP132 [160,161], Sp1 [153,162] or CREB [86,163,164] allows recruitment of the CBP/p300 coactivator which interconnects multiple cell signalling pathways [165]. This may participate to the cAMP responsiveness of some SF-1 target genes.

At last, a third interaction group allows repression of SF-1 activated genes. DAX-1 is the paradigm of such repressors. It encodes a peculiar nuclear receptor devoid of a classical DNA binding domain, which is replaced by three-and-a half repeats of an alanine and glycine-rich motif [166,167]. DAX-1 overexpression subsequent to Xp21 duplication, induces male to female sex reversal in

humans [168,169], a phenotype that can be mimicked by Dax-1 overexpression in transgenic mice with a poor Sry allele [170]. DAX-1 mutations in humans are responsible for adrenal hypoplasia congenita as well as hypogonadotrophic hypogonadism suggesting that DAX-1 may perform similar functions as SF-1 [171]. Indeed, SF-1 and Dax-1 are coexpressed in steroidogenic tissues as well as in the VMH and pituitary, early in development [47,172,173]. However, when overexpressed in Y1 adrenocortical cells, DAX-1 markedly impairs steroidogenic output and transcriptionally represses the promoters of SF-1 target genes such as StAR, P450scc, 3 β -HSD [174,175] and *akr1-b7* [92]. Essentially two mechanisms have been proposed for DAX-1 mediated transcriptional repression, although they are probably not mutually exclusive. DAX-1 can repress SF-1 target genes expression either by binding DNA to hairpin-like structures [176], or by physically interacting with SF-1, independently of the DNA context [107]. This interaction implies a carboxy-terminal repression domain (437 to 447) and a proximal interaction domain of SF-1 (226 to 230) [152] (figure 1) that contact amino-terminal LXXLL domains of DAX-1 [151,177]. This physical interaction allows the recruitment of the corepressors NcoR [152] and Alien [178] to SF-1-responsive genes promoters. The physiological relevance of such a negative functional interaction between Dax-1 and SF-1 is as yet unclear as Dax-1 knock-out in mice does not lead to marked adrenal defects [179]. However, it is noteworthy

that Dax-1 ablation in SF-1 haploinsufficient mice allows a reversion of the histological and functional adrenal defects, suggesting that the two receptors interact *in vivo* [180]. Furthermore, we have been able to observe Dax-1 downregulation in either ACTH-treated mice or adrenocortical ATC-1 cells that naturally express Dax-1, indicating that this receptor may be implicated in hormonal responsiveness *in vivo* (B. Ragazzon, personal communication).

An unexpected repressor of SF-1 activity is the androgen receptor. The increase in plasmatic LH concentrations which is induced by GnRH leads to increased sex steroid production by the gonads. In turn, sex steroids exert a negative feedback on GnRH and LH synthesis (figure 6). Recently, Jorgensen and Nilson, have elegantly demonstrated that androgen receptor was able to repress LH- β promoter transactivation by interacting with SF-1 LBD [154]. Under low GnRH conditions, AR blocks the functional interaction between SF-1 and Ptx1/Egr-1. When GnRH concentrations in pituitary gonadotropes increase, Egr-1 expression is induced [156] and allows recruitment of Ptx-1 as well as AR displacement, resulting in the formation of an activating complex composed of SF-1, Egr-1 and Ptx1. When circulating androgens increase, activated AR displaces Egr-1 and Ptx1, thus repressing LH- β transcription in response to SF-1 [154]. This model (figure 6) perfectly illustrates the complex interactions that are required for SF-1 target genes activation. It is likely that such mechanisms may participate to the control of SF-1 target genes expression in response to cAMP increases.

Post-translational SF-1 alterations

Although it is clear that SF-1 transcriptional activity requires complex interactions with numerous cofactors, the mechanisms underlying the recruitment of these partners are still unclear. Because PKA is implicated in the stimulation of most of SF-1 target genes expression, its role in SF-1 activity has been extensively investigated. *In vivo*, SF-1 is phosphorylated in response to granulosa cells stimulation by FSH [86]. *In vitro*, PKA can phosphorylate SF-1 LBD and N-terminal region [101,135]. Although SF-1 seems to be implicated in the cAMP responsiveness of the rat CYP17 gene, its *in vitro* phosphorylation by PKA decreases its DNA binding capacity, an observation which is not compatible with its activating role [101,135]. In heterologous cell systems SF-1 is phosphorylated on serine 203 by the MAPK ERK2, regardless of the presence of cAMP. This residue is situated in the proximal activation domain, the integrity of which is essential for SF-1 activity. Serine 203 phosphorylation is required for SF-1 transcriptional activity and allows the recruitment of two cofactors, the coactivator GRIP1/TIF2 and the corepressor SMRT [25]. Recently, Desclozeaux et al., have shown that SF-1 hinge and helix 1 of the LBD were able to set helices

2 to 12 of the LBD in an active conformation reminiscent of ligand-activated nuclear receptors, albeit in the absence of a ligand. Helices 2 to 12 recruitment is enhanced by MAPK stimulation and decreased by mutating serine 203, or in the presence of MKP-1, a MAPK specific phosphatase. At last, serine 203 phosphorylation stabilizes SF-1 LBD, an observation reminiscent of ligand-activated nuclear receptors [18]. This shows that apart from being implicated in cofactor recruitment [25] serine 203 phosphorylation also structures and stabilizes SF-1 LBD. However, these experiments do not establish a link between cAMP stimulation and SF-1 activity. This may depend on activation of the MAPK pathway by PKA [181]. Indeed, cAMP-induced StAR transcription is dependent on activation of the MAPK pathway in Y1 and MA-10 cells. This activation induces SF-1 phosphorylation *in vivo* in Y1 cells, resulting in an increase in SF-1 binding in EMSA [182]. However, cAMP-induced P450_{scc} expression does not seem to depend on MAPK activation in the same experiments [182]. Furthermore, cAMP pathway stimulation in H295 cells results in a decrease in SF-1 overall phosphorylation [183], indicating that PKA/MAPK crossovers may be gene and cell-specific. Thus in H295 cells, MAPK inhibition by the specific inhibitor PD98059 does not reduce, but on the contrary, stimulates hCYP17 transcription [183]. Indeed, StAR and hCYP17 cAMP-stimulated transcription in H295 cells is dependent on protein phosphatase activities [183,184]. In H295 cells, MKP-1 that can be phosphorylated by PKA *in vitro*, is overexpressed in response to cAMP stimulation. MKP-1 overexpression leads to an increase in hCYP17 expression, whereas MKP-1 inhibition by an antisense RNA prevents hCYP17 induction by cAMP. Whether MKP-1 is directly implicated in SF-1 activity is still unclear. However, it is noteworthy that phosphatase inhibitors decrease SF-1 transcriptional activity on the hCYP17 promoter, indicating that at least one phosphatase is required for promoter activation by SF-1 [185].

Altogether, these results seem rather contradictory. Although it is probable that the MAPK pathway influences SF-1 activity, it is still unclear whether this implicates direct phosphorylation of SF-1 by a MAPK. Also, it seems that such a mechanism would not necessarily apply to all cell types or promoters. One pitfall of these experiments is that the MAPK pathway is highly sensitive to extracellular changes and temporal variations in the experimental setting. Completely different experimental conditions may thus account for the contradictory observations. At last, future experiments may distinguish between overall SF-1 phosphorylation and phosphorylation on specific residues such as serine 203. When these mechanisms are deciphered, it will be interesting to study the effect of one particular phosphorylation or dephosphorylation on the

Figure 6

A model for LHβ promoter repression by a physical interaction between AR and SF-1. (After Jorgensen and Nilsson, Ref. [201]) In the presence of elevated androgen concentrations, AR (androgen receptor) interacts with SF-1 on LHβ promoter, preventing interaction of Egr-1 with its response elements. LHβ is then turned off. A GnRH pulse (resulting from a reduction in circulating androgen concentrations), favours Egr-1 transcription, increasing its accumulation. In turn, Egr-1 displaces AR from SF-1 and favours an active setting of transcription factors on LHβ promoter. LHβ transcription is then triggered. The resulting LH protein production in turn stimulates androgens production by the gonads.

recruitment of cofactors such as p/CIP *versus* TIF2 in response to cAMP stimulation.

Another emerging activation control mechanism for nuclear receptors is their acetylation [186]. SF-1 is acetylated *in vivo* in a heterologous cell system and inter-

acts with the acetyl-transferase GCN5, which can acetylate SF-1 *in vitro*. Although SF-1-dependent activation of a reporter gene may depend on SF-1 acetylation in the presence of GCN5, experimental results obtained by mutating the potential acetylation sites or by the use of the deacetylase inhibitor trichostatin A, are contradictory [147]. If more substantial data is obtained regarding the role of acetylation on SF-1 activity, it will be interesting to study the implication of certain histone acetyl transferase (HAT) coactivators such as CBP/p300, in SF-1 acetylation *in vivo*.

Conclusions

A key role for SF-1, in the differentiation and the maintenance of the differentiated function of the gonads, adrenals and particular regions of the pituitary and hypothalamus is now clearly established (table 1). Its targets implicated in the maintenance of the differentiated function of steroidogenic tissues and in sex determination are now, at least in part, identified. Tissue-specific SF-1 knock-out at late developmental stages or at adulthood (when differentiated function is established) may confirm the results of transient transfections and may allow the identification of new SF-1 targets.

Although tremendous progress has been accomplished since SF-1 cloning, major questions remain unanswered. Indeed, genes whose down-regulation (or up-regulation) in SF-1 null mice may account for the regression of gonadal, adrenal and VMH anlagen are still unidentified. Another important issue is the identification of the mechanisms that allow activation of this orphan nuclear receptor at certain stages during embryonic and post-natal development or in response to external stimuli such as increased cAMP concentrations evoked by trophic hormones in their target tissues. Recent results of our group show that a SF-1 binding site is dispensable at birth for *akr1-b7* promoter activity but is required 20 days later [42]. On the contrary, Hoyle et al., show that a SF-1 binding site is required for early developmental expression of DAX-1, but is dispensable after birth [187]. Forthcoming studies will require a careful evaluation of the distinct roles of SF-1 during early development and after birth.

Competing interests

None declared.

Authors' Contributions

P.V. wrote this article as part of is thesis manuscript.

A.M. and A-M. L-M. are P.V. PhD supervisors. They helped him with writing this manuscript.

G.V. is the head of the PCEM team.

References

1. Morohashi K, Honda S, Inomata Y, Handa H and Omura T: **A common trans-acting factor, Ad4-binding protein, to the promoters of steroidogenic P-450s.** *J Biol Chem* 1992, **267**:17913-9.
2. Rice DA, Mouw AR, Bogerd AM and Parker KL: **A shared promoter element regulates the expression of three steroidogenic enzymes.** *Mol Endocrinol* 1991, **5**:1552-61.
3. Honda S, Morohashi K, Nomura M, Takeya H, Kitajima M and Omura T: **Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor superfamily.** *J Biol Chem* 1993, **268**:7494-502.
4. Lavorgna G, Karim FD, Thummel CS and Wu C: **Potential role for a FTZ-F1 steroid receptor superfamily member in the control of Drosophila metamorphosis.** *Proc Natl Acad Sci U S A* 1993, **90**:3004-8.
5. Laudet V: **Evolution of the nuclear receptor superfamily: early diversification from an ancestral orphan receptor.** *J Mol Endocrinol* 1997, **19**:207-26.
6. De Mendonca RL, Bouton D, Bertin B, Escriva H, Noel C, Vanacker JM, Cornette J, Laudet V and Pierce RJ: **A functionally conserved member of the FTZ-F1 nuclear receptor family from Schistosoma mansoni.** *Eur J Biochem* 2002, **269**:5700-11.
7. Kotomura N, Ninomiya Y, Umesono K and Niwa O: **Transcriptional regulation by competition between ELP isoforms and nuclear receptors.** *Biochem Biophys Res Commun* 1997, **230**:407-12.
8. Ninomiya Y, Okada M, Kotomura N, Suzuki K, Tsukiyama T and Niwa O: **Genomic organization and isoforms of the mouse ELP gene.** *J Biochem (Tokyo)* 1995, **118**:380-9.
9. Luo X, Ikeda Y, Schlosser DA and Parker KL: **Steroidogenic factor I is the essential transcript of the mouse Ftz-F1 gene.** *Mol Endocrinol* 1995, **9**:1233-9.
10. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M and Chambon P et al.: **The nuclear receptor superfamily: the second decade.** *Cell* 1995, **83**:835-9.
11. Hammer GD and Ingraham HA: **Steroidogenic factor-I: its role in endocrine organ development and differentiation.** *Front Neuroendocrinol* 1999, **20**:199-223.
12. Wilson TE, Fahrner TJ and Milbrandt J: **The orphan receptors NGFI-B and steroidogenic factor I establish monomer binding as a third paradigm of nuclear receptor-DNA interaction.** *Mol Cell Biol* 1993, **13**:5794-804.
13. Nitta M, Ku S, Brown C, Okamoto AY and Shan B: **CPF: an orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7alpha-hydroxylase gene.** *Proc Natl Acad Sci U S A* 1999, **96**:6660-5.
14. Li LA, Chiang EF, Chen JC, Hsu NC, Chen YJ and Chung BC: **Function of steroidogenic factor I domains in nuclear localization, transactivation, and interaction with transcription factor TFIIB and c-Jun.** *Mol Endocrinol* 1999, **13**:1588-98.
15. Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, Gurakan B and Jameson JL: **Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-I, in a dose-dependent manner.** *J Clin Endocrinol Metab* 2002, **87**:1829-33.
16. Mellon SH and Bair SR: **25-Hydroxycholesterol is not a ligand for the orphan nuclear receptor steroidogenic factor-I (SF-I).** *Endocrinology* 1998, **139**:3026-9.
17. Giguere V: **Orphan nuclear receptors: from gene to function.** *Endocr Rev* 1999, **20**:689-725.
18. Desclozeaux M, Krylova IN, Horn F, Fletterick RJ and Ingraham HA: **Phosphorylation and intramolecular stabilization of the ligand-binding domain in the nuclear receptor steroidogenic factor I.** *Mol Cell Biol* 2002, **22**:7193-203.
19. Ito M, Yu RN and Jameson JL: **Steroidogenic factor-I contains a carboxy-terminal transcriptional activation domain that interacts with steroid receptor coactivator-I.** *Mol Endocrinol* 1998, **12**:290-301.
20. Crawford PA, Polish JA, Ganpule G and Sadovsky Y: **The activation function-2 hexamer of steroidogenic factor-I is required, but not sufficient for potentiation by SRC-1.** *Mol Endocrinol* 1997, **11**:1626-35.
21. Li LA, Lala D and Chung BC: **Function of steroidogenic factor I (SFI) ligand-binding domain in gene activation and interaction with API.** *Biochem Biophys Res Commun* 1998, **250**:318-20.

22. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ and Lazar MA: **Interdomain communication regulating ligand binding by PPAR-gamma.** *Nature* 1998, **396**:377-80.
23. He B and Wilson EM: **The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor.** *Mol Genet Metab* 2002, **75**:293-8.
24. He B, Bowen NT, Minges JT and Wilson EM: **Androgen-induced NH2- and COOH-terminal Interaction Inhibits p160 coactivator recruitment by activation function 2.** *J Biol Chem* 2001, **276**:42293-301.
25. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL and Ingraham HA: **Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress.** *Mol Cell* 1999, **3**:521-6.
26. Ikeda Y, Shen WH, Ingraham HA and Parker KL: **Developmental expression of mouse steroidogenic factor-1, an essential regulator of the steroid hydroxylases.** *Mol Endocrinol* 1994, **8**:654-62.
27. Hatano O, Takayama K, Imai T, Waterman MR, Takakusu A, Omura T and Morohashi K: **Sex-dependent expression of a transcription factor, Ad4BP, regulating steroidogenic P-450 genes in the gonads during prenatal and postnatal rat development.** *Development* 1994, **120**:2787-97.
28. Hatano O, Takakusu A, Nomura M and Morohashi K: **Identical origin of adrenal cortex and gonad revealed by expression profiles of Ad4BP/SF-1.** *Genes Cells* 1996, **1**:663-71.
29. Sadovsky Y, Crawford PA, Woodson KG, Polish JA, Clements MA, Tourtellotte LM, Simburger K and Milbrandt J: **Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain-cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids.** *Proc Natl Acad Sci U S A* 1995, **92**:10939-43.
30. Ikeda Y, Lala DS, Luo X, Kim E, Moisan MP and Parker KL: **Characterization of the mouse FTZ-F1 gene, which encodes a key regulator of steroid hydroxylase gene expression.** *Mol Endocrinol* 1993, **7**:852-60.
31. Ramayya MS, Zhou J, Kino T, Segars JH, Bondy CA and Chrousos GP: **Steroidogenic factor 1 messenger ribonucleic acid expression in steroidogenic and nonsteroidogenic human tissues: Northern blot and in situ hybridization studies.** *J Clin Endocrinol Metab* 1997, **82**:1799-806.
32. Ben-Zimra M, Koler M and Orly J: **Transcription of cholesterol side-chain cleavage cytochrome P450 in the placenta: activating protein-2 assumes the role of steroidogenic factor-1 by binding to an overlapping promoter element.** *Mol Endocrinol* 2002, **16**:1864-80.
33. Ingraham HA, Lala DS, Ikeda Y, Luo X, Shen WH, Nachtigal MW, Abbud R, Nilson JH and Parker KL: **The nuclear receptor steroidogenic factor 1 acts at multiple levels of the reproductive axis.** *Genes Dev* 1994, **8**:2302-12.
34. Shinoda K, Lei H, Yoshii H, Nomura M, Nagano M, Shiba H, Sasaki H, Osawa Y, Ninomiya Y and Niwa O *et al.*: **Developmental defects of the ventromedial hypothalamic nucleus and pituitary gonadotroph in the Ftz-F1 disrupted mice.** *Dev Dyn* 1995, **204**:22-9.
35. Ikeda Y, Luo X, Abbud R, Nilson JH and Parker KL: **The nuclear receptor steroidogenic factor 1 is essential for the formation of the ventromedial hypothalamic nucleus.** *Mol Endocrinol* 1995, **9**:478-86.
36. Patel MV, McKay IA and Burren JM: **Transcriptional regulators of steroidogenesis, DAX-1 and SF-1, are expressed in human skin.** *J Invest Dermatol* 2001, **117**:1559-65.
37. Courchay G, Boyera N, Bernard BA and Mahe Y: **Messenger RNA expression of steroidogenesis enzyme subtypes in the human pilosebaceous unit.** *Skin Pharmacol* 1996, **9**:169-76.
38. Slominski A, Ermak G and Mihm M: **ACTH receptor, CYP11A1, CYP17 and CYP21A2 genes are expressed in skin.** *J Clin Endocrinol Metab* 1996, **81**:2746-9.
39. Venencie PY, Meduri G, Pissard S, Jolivet A, Loosfelt H, Milgrom E and Misrahi M: **Luteinizing hormone/human chorionic gonadotrophin receptors in various epidermal structures.** *Br J Dermatol* 1999, **141**:438-46.
40. Morohashi K, Tsuboi-Asai H, Matsushita S, Suda M, Nakashima M, Sasano H, Hataba Y, Li CL, Fukata J and Irie J *et al.*: **Structural and functional abnormalities in the spleen of an mFtz-F1 gene-disrupted mouse.** *Blood* 1999, **93**:1586-94.
41. Wotus C, Levay-Young BK, Rogers LM, Gomez-Sanchez CE and Engeland WC: **Development of adrenal zonation in fetal rats defined by expression of aldosterone synthase and 11 β -hydroxylase.** *Endocrinology* 1998, **139**:4397-4403.
42. Martinez A, Val P, Sahut-Barnola I, Aigueperse C, Veyssiere G and Lefrancois Martinez AM: **SF-1 controls the aldose reductase akr1b7 gene promoter in transgenic mice through an atypical binding site.** *Endocrinology* 2003, **144**:2111-2120.
43. Okimoto DK, Blaus A, Schmidt M, Gordon MK, Dent GW and Levine S: **Differential expression of c-fos and tyrosine hydroxylase mRNA in the adrenal gland of the infant rat: evidence for an adrenal hyporesponsive period.** *Endocrinology* 2002, **143**:1717-25.
44. Hanley NA, Ball SG, Clement-Jones M, Hagan DM, Strachan T, Lindsay S, Robson S, Ostrer H, Parker KL and Wilson DI: **Expression of steroidogenic factor 1 and Wilms' tumour 1 during early human gonadal development and sex determination.** *Mech Dev* 1999, **87**:175-80.
45. de Santa Barbara P, Moniot B, Poulat F and Berta P: **Expression and subcellular localization of SF-1, SOX9, WT1, and AMH proteins during early human testicular development.** *Dev Dyn* 2000, **217**:293-8.
46. Mesiano S and Jaffe RB: **Role of growth factors in the developmental regulation of the human fetal adrenal cortex.** *Steroids* 1997, **62**:62-72.
47. Hanley NA, Rainey WE, Wilson DI, Ball SG and Parker KL: **Expression profiles of SF-1, DAX1, and CYP17 in the human fetal adrenal gland: potential interactions in gene regulation.** *Mol Endocrinol* 2001, **15**:57-68.
48. Roselli CE, Jorgensen EZ, Doyle MW and Ronnekleiv OK: **Expression of the orphan receptor steroidogenic factor-1 mRNA in the rat medial basal hypothalamus.** *Brain Res Mol Brain Res* 1997, **44**:66-72.
49. Stallings NR, Hanley NA, Majdic G, Zhao L, Bakke M and Parker KL: **Development of a transgenic green fluorescent protein lineage marker for steroidogenic factor 1.** *Endocr Res* 2002, **28**:497-504.
50. Luo X, Ikeda Y and Parker KL: **A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation.** *Cell* 1994, **77**:481-90.
51. Dellovade TL, Young M, Ross EP, Henderson R, Caron K, Parker K and Tobet SA: **Disruption of the gene encoding SF-1 alters the distribution of hypothalamic neuronal phenotypes.** *J Comp Neurol* 2000, **423**:579-89.
52. Majdic G, Young M, Gomez-Sanchez E, Anderson P, Szczepaniak LS, Dobbins RL, McGarry JD and Parker KL: **Knockout mice lacking steroidogenic factor 1 are a novel genetic model of hypothalamic obesity.** *Endocrinology* 2002, **143**:607-14.
53. Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA and Parker KL: **Steroidogenic factor 1 (SF1) is essential for pituitary gonadotrope function.** *Development* 2001, **128**:147-54.
54. Zhao L, Bakke M and Parker KL: **Pituitary-specific knockout of steroidogenic factor 1.** *Mol Cell Endocrinol* 2001, **185**:27-32.
55. Zhao L, Bakke M, Krimkevich Y, Cushman LJ, Parlow AF, Camper SA and Parker KL: **Hypomorphic phenotype in mice with pituitary-specific knockout of steroidogenic factor 1.** *Genesis* 2001, **30**:65-9.
56. Barnhart KM and Mellon PL: **The orphan nuclear receptor, steroidogenic factor-1, regulates the glycoprotein hormone alpha-subunit gene in pituitary gonadotropes.** *Mol Endocrinol* 1994, **8**:878-85.
57. Halvorson LM, Kaiser UB and Chin WW: **Stimulation of luteinizing hormone beta gene promoter activity by the orphan nuclear receptor, steroidogenic factor-1.** *J Biol Chem* 1996, **271**:6645-50.
58. Keri RA and Nilson JH: **A steroidogenic factor-1 binding site is required for activity of the luteinizing hormone beta subunit promoter in gonadotropes of transgenic mice.** *J Biol Chem* 1996, **271**:10782-5.
59. Brown P and McNeilly AS: **Steroidogenic factor-1 (SF-1) and the regulation of expression of luteinising hormone and follicle stimulating hormone b-subunits in the sheep anterior pituitary in vivo.** *Int J Biochem Cell Biol* 1997, **29**:1513-24.

60. Levallet J, Koskimies P, Rahman N and Huhtaniemi I: **The promoter of murine follicle-stimulating hormone receptor: functional characterization and regulation by transcription factor steroidogenic factor 1.** *Mol Endocrinol* 2001, **15**:80-92.
61. Pincas H, Laverriere JN and Counis R: **Pituitary adenylate cyclase-activating polypeptide and cyclic adenosine 3',5'-monophosphate stimulate the promoter activity of the rat gonadotropin-releasing hormone receptor gene via a bipartite response element in gonadotrope-derived cells.** *J Biol Chem* 2001, **276**:23562-71.
62. Pincas H, Amoyel K, Counis R and Laverriere JN: **Proximal cis-acting elements, including steroidogenic factor 1, mediate the efficiency of a distal enhancer in the promoter of the rat gonadotropin-releasing hormone receptor gene.** *Mol Endocrinol* 2001, **15**:319-37.
63. Ngan ES, Cheng PK, Leung PC and Chow BK: **Steroidogenic factor-1 interacts with a gonadotrope-specific element within the first exon of the human gonadotropin-releasing hormone receptor gene to mediate gonadotrope-specific expression.** *Endocrinology* 1999, **140**:2452-62.
64. Kendall SK, Saunders TL, Jin L, Lloyd RV, Glode LM, Nett TM, Keri RA, Nilson JH and Camper SA: **Targeted ablation of pituitary gonadotropes in transgenic mice.** *Mol Endocrinol* 1991, **5**:2025-36.
65. Brobeck JR: **Mechanism of the development of obesity in animals with hypothalamic lesions.** *Physiol Rev* 1946, **26**:541-559.
66. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L and Keller GA et al.: **Identification of an angiogenic mitogen selective for endocrine gland endothelium.** *Nature* 2001, **412**:877-84.
67. Achermann JC, Ito M, Hindmarsh PC and Jameson JL: **A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans.** *Nat Genet* 1999, **22**:125-6.
68. Biason-Lauber A and Schoenle EJ: **Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency.** *Am J Hum Genet* 2000, **67**:1563-8.
69. Bland ML, Jamieson CA, Akana SF, Bornstein SR, Eisenhofer G, Dallman MF and Ingraham HA: **Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response.** *Proc Natl Acad Sci U S A* 2000, **97**:14488-93.
70. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J and Mangelsdorf DJ: **Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.** *Mol Cell* 2000, **6**:507-15.
71. Wang ZN, Bassett M and Rainey WE: **Liver receptor homologue-1 is expressed in the adrenal and can regulate transcription of 11 beta-hydroxylase.** *J Mol Endocrinol* 2001, **27**:255-8.
72. Falender AE, Lanz R, Malenfant D, Belanger L and Richards JS: **Differential expression of steroidogenic factor-1 and FTF/LRH-1 in the rodent ovary.** *Endocrinology* 2003, **144**:3598-3610.
73. Sirianni R, Seely JB, Attia G, Stocco DM, Carr BR, Pezzi V and Rainey WE: **Liver receptor homologue-1 is expressed in human steroidogenic tissues and activates transcription of genes encoding steroidogenic enzymes.** *J Endocrinol* 2002, **174**:R13-7.
74. Crawford PA, Sadvovsky Y and Milbrandt J: **Nuclear receptor steroidogenic factor 1 directs embryonic stem cells toward the steroidogenic lineage.** *Mol Cell Biol* 1997, **17**:3997-4006.
75. Beuschlein F, Mutch C, Bavers DL, Ulrich-Lai YM, Engeland WC, Keegan C and Hammer GD: **Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy.** *Endocrinology* 2002, **143**:3122-35.
76. Bicknell AB, Lomthaisong K, Woods RJ, Hutchinson EG, Bennett HP, Gladwell RT and Lowry PJ: **Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth.** *Cell* 2001, **105**:903-12.
77. Kelman Z: **PCNA: structure, functions and interactions.** *Oncogene* 1997, **14**:629-40.
78. Bassett MH, Zhang Y, Clyne C, White PC and Rainey WE: **Differential regulation of aldosterone synthase and 11 beta-hydroxylase transcription by steroidogenic factor-1.** *J Mol Endocrinol* 2002, **28**:125-35.
79. Hu MC, Hsu NC, Pai CI, Wang CK and Chung B: **Functions of the upstream and proximal steroidogenic factor 1 (SF-1)-binding sites in the CYP11A1 promoter in basal transcription and hormonal response.** *Mol Endocrinol* 2001, **15**:812-8.
80. Gizard F, El-Alfy M, Duguay Y, Lavallee B, DeWitte F, Staels B, Beatty BG and Hum DW: **Function of the transcriptional regulating protein of 132 kDa (TRP-132) on human P450scc gene expression.** *Endocr Res* 2002, **28**:559-74.
81. Wang XL, Bassett M, Zhang Y, Yin S, Clyne C, White PC and Rainey WE: **Transcriptional regulation of human 11 beta-hydroxylase (hCYP11B1).** *Endocrinology* 2000, **141**:3587-94.
82. Sewer MB and Waterman MR: **Transcriptional complexes at the CYP17 CRS.** *Endocr Res* 2002, **28**:551-8.
83. Jacob AL and Lund J: **Mutations in the activation function-2 core domain of steroidogenic factor-1 dominantly suppresses PKA-dependent transactivation of the bovine CYP17 gene.** *J Biol Chem* 1998, **273**:13391-4.
84. Bakke M and Lund J: **Mutually exclusive interactions of two nuclear orphan receptors determine activity of a cyclic adenosine 3',5'-monophosphate-responsive sequence in the bovine CYP17 gene.** *Mol Endocrinol* 1995, **9**:327-39.
85. Michael MD, Kilgore MW, Morohashi K and Simpson ER: **Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (P1) of the human aromatase P450 (CYP19) gene in the ovary.** *J Biol Chem* 1995, **270**:13561-6.
86. Carlone DL and Richards JS: **Functional interactions, phosphorylation, and levels of 3',5'-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells.** *Mol Endocrinol* 1997, **11**:292-304.
87. Pfeifer SM, Furth EE, Ohba T, Chang YJ, Rennert H, Sakuragi N, Billheimer JT and Strauss JF 3rd: **Steroid carrier protein 2: a role in steroid hormone synthesis?** *J Steroid Biochem Mol Biol* 1993, **47**:167-72.
88. Stocco DM: **Intramitochondrial cholesterol transfer.** *Biochim Biophys Acta* 2000, **1486**:184-97.
89. Mascaro C, Nadal A, Hegardt FG, Marrero PF and Haro D: **Contribution of steroidogenic factor 1 to the regulation of cholesterol synthesis.** *Biochem J* 2000, **350**(Pt 3):785-90.
90. Martinez A, Val P, Jean C, Veyssiere G and Lefrancois-Martinez AM: **SF-1 controls the expression of the scavenger gene akrlb7: in vitro and in vivo approaches.** *Endocr Res* 2002, **28**:515-8.
91. Val P, Aigueperse C, Lefrancois-Martinez AM, Jean C, Veyssiere G and Martinez A: **Role of three SF-1 binding sites in the expression of the mvpd/akrl-b7 isocaproaldehyde reductase in Y1 cells.** *Endocr Res* 2002, **28**:527-33.
92. Aigueperse C, Val P, Pacot C, Darne C, Lalli E, P Sassone-Corsi, Veyssiere G, Jean C and Martinez A: **SF-1 (steroidogenic factor-1), C/EBPbeta (CCAAT/enhancer binding protein), and ubiquitous transcription factors NF1 (nuclear factor 1) and Sp1 (selective promoter factor 1) are required for regulation of the mouse aldose reductase-like gene (AKR1B7) expression in adrenocortical cells.** *Mol Endocrinol* 2001, **15**:93-111.
93. Lefrancois-Martinez AM, Tournaire C, Martinez A, Berger M, Daoudal S, Tritsch D, Veyssiere G and Jean C: **Product of side-chain cleavage of cholesterol, isocaproaldehyde, is an endogenous specific substrate of mouse vas deferens protein, an aldose reductase-like protein in adrenocortical cells.** *J Biol Chem* 1999, **274**:32875-80.
94. Chinn AM, Ciais D, Bailly S, Chambaz E, LaMarre J and Feige JJ: **Identification of two novel ACTH-responsive genes encoding manganese-dependent superoxide dismutase (SOD2) and the zinc finger protein TIS11b [tetradecanoyl phorbol acetate (TPA)-inducible sequence 11b].** *Mol Endocrinol* 2002, **16**:1417-27.
95. McCann SM, Haens G, Mastronardi C, Walczewska A, Karanth S, Rettori V and Yu WH: **The Role of Nitric Oxide (NO) in Control of LHRH Release that Mediates Gonadotropin Release and Sexual Behavior.** *Curr Pharm Des* 2003, **9**:381-90.
96. Wei X, Sasaki M, Huang H, Dawson VL and Dawson TM: **The orphan nuclear receptor, steroidogenic factor 1, regulates neuronal nitric oxide synthase gene expression in pituitary gonadotropes.** *Mol Endocrinol* 2002, **16**:2828-39.
97. Ando H, Hew CL and Urano A: **Signal transduction pathways and transcription factors involved in the gonadotropin-releasing hormone-stimulated gonadotropin subunit gene**

- expression. *Comp Biochem Physiol B Biochem Mol Biol* 2001, **129**:525-32.
98. Swain A and Lovell-Badge R: **Mammalian sex determination: a molecular drama.** *Genes Dev* 1999, **13**:755-67.
 99. Albrecht KH and Eicher EM: **Evidence that Sry is expressed in pre-Sertoli cells and Sertoli and granulosa cells have a common precursor.** *Dev Biol* 2001, **240**:92-107.
 100. Swain A and Lovell-Badge R: **Sex determination and differentiation.** In: *Mouse Development* 2002, **17**:371-393.
 101. de Santa Barbara P, Mejean C, Moniot B, Males MH, Berta P and Boizet-Bonhoure B: **Steroidogenic factor-I contributes to the cyclic-adenosine monophosphate down-regulation of human SRY gene expression.** *Biol Reprod* 2001, **64**:775-83.
 102. Pilon N, Daneau I, Paradis V, Hamel F, Lussier JG, Viger RS and Silverides DW: **Porcine SRY Promoter Is a Target for Steroidogenic Factor I.** *Biol Reprod* 2003, **68**:1098-106.
 103. Capel B: **Sex in the 90s: SRY and the switch to the male pathway.** *Annu Rev Physiol* 1998, **60**:497-523.
 104. Shen WH, Moore CC, Ikeda Y, Parker KL and Ingraham HA: **Nuclear receptor steroidogenic factor I regulates the Mullerian inhibiting substance gene: a link to the sex determination cascade.** *Cell* 1994, **77**:651-61.
 105. De Santa Barbara P, Bonneaud N, Boizet B, Desclozeaux M, Moniot B, Sudbeck P, Scherer G, Poulat F and Berta P: **Direct interaction of SRY-related protein SOX9 and steroidogenic factor I regulates transcription of the human anti-Mullerian hormone gene.** *Mol Cell Biol* 1998, **18**:6653-65.
 106. Tremblay JJ and Viger RS: **Transcription factor GATA-4 enhances Mullerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-I.** *Mol Endocrinol* 1999, **13**:1388-401.
 107. Nachtigal MW, Hirokawa Y, Enyeart-VanHouten DL, Flanagan JN, Hammer GD and Ingraham HA: **Wilms' tumor I and Dax-I modulate the orphan nuclear receptor SF-I in sex-specific gene expression.** *Cell* 1998, **93**:445-54.
 108. Arango NA, Lovell-Badge R and Behringer RR: **Targeted mutagenesis of the endogenous mouse Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development.** *Cell* 1999, **99**:409-19.
 109. Zimmermann S, Schwarzer A, Buth S, Engel W and Adham IM: **Transcription of the Leydig insulin-like gene is mediated by steroidogenic factor-I.** *Mol Endocrinol* 1998, **12**:706-13.
 110. Koskimies P, Levallet J, Sipila P, Huhtaniemi I and Poutanen M: **Murine relaxin-like factor promoter: functional characterization and regulation by transcription factors steroidogenic factor I and DAX-I.** *Endocrinology* 2002, **143**:909-19.
 111. Amsterdam A, Tajima K and Sasson R: **Cell-specific regulation of apoptosis by glucocorticoids: implication to their anti-inflammatory action.** *Biochem Pharmacol* 2002, **64**:843-50.
 112. Reinhart AJ, Williams SC, Clark BJ and Stocco DM: **SF-I (steroidogenic factor-I) and C/EBP beta (CCAAT/enhancer binding protein-beta) cooperate to regulate the murine StAR (steroidogenic acute regulatory) promoter.** *Mol Endocrinol* 1999, **13**:729-41.
 113. Hasegawa T, Zhao L, Caron KM, Majdic G, Suzuki T, Shizawa S, Sasano H and Parker KL: **Developmental roles of the steroidogenic acute regulatory protein (StAR) as revealed by StAR knockout mice.** *Mol Endocrinol* 2000, **14**:1462-71.
 114. Hu MC, Hsu NC, El Hadj NB, Pai C, Chu HP, Wang CK and Chung BC: **Steroid deficiency syndromes in mice with targeted disruption of Cyp11a1.** *Mol Endocrinol* 2002, **16**:1943-50.
 115. Yaswen L, Diehl N, Brennan MB and Hochgeschwender U: **Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin.** *Nat Med* 1999, **5**:1066-70.
 116. Bicknell AB and Lowry PJ: **Adrenal growth is controlled by expression of specific pro-opiomelanocortin serine protease in the outer adrenal cortex.** *Endocr Res* 2002, **28**:589-95.
 117. Pignatelli D, Ferreira J, Vendeira P, Magalhaes MC and Vinson GP: **Proliferation of capsular stem cells induced by ACTH in the rat adrenal cortex.** *Endocr Res* 2002, **28**:683-91.
 118. Bicknell AB: **Identification of a receptor for N-POMC peptides.** *Endocr Res* 2002, **28**:309-14.
 119. Lala DS, Syka PM, Lazarchik SB, Mangelsdorf DJ, Parker KL and Heyman RA: **Activation of the orphan nuclear receptor steroidogenic factor I by oxysterols.** *Proc Natl Acad Sci U S A* 1997, **94**:4895-900.
 120. Woodson KG, Crawford PA, Sadovsky Y and Milbrandt J: **Characterization of the promoter of SF-I, an orphan nuclear receptor required for adrenal and gonadal development.** *Mol Endocrinol* 1997, **11**:117-26.
 121. Scherrer SP, Rice DA and Heckert LL: **Expression of steroidogenic factor I in the testis requires an interactive array of elements within its proximal promoter.** *Biol Reprod* 2002, **67**:1509-21.
 122. Nomura M, Bartsch S, Nawata H, Omura T and Morohashi K: **An E box element is required for the expression of the ad4bp gene, a mammalian homologue of ftz-fl gene, which is essential for adrenal and gonadal development.** *J Biol Chem* 1995, **270**:7453-61.
 123. Harris AN and Mellon PL: **The basic helix-loop-helix, leucine zipper transcription factor, USF (upstream stimulatory factor), is a key regulator of SF-I (steroidogenic factor-I) gene expression in pituitary gonadotrope and steroidogenic cells.** *Mol Endocrinol* 1998, **12**:714-26.
 124. Oba K, Yanase T, Ichino I, Goto K, Takayanagi R and Nawata H: **Transcriptional regulation of the human FTZ-FI gene encoding Ad4BP/SF-I.** *J Biochem (Tokyo)* 2000, **128**:517-28.
 125. Nomura M, Nawata H and Morohashi K: **Autoregulatory loop in the regulation of the mammalian ftz-fl gene.** *J Biol Chem* 1996, **271**:8243-9.
 126. Zubair M, Oka S, Ishihara S and Morohashi K: **Analysis of Ad4BP/SF-I gene regulatory region.** *Endocr Res* 2002, **28**:535.
 127. Quaggin SE, Schwartz L, Cui S, Igarashi P, Deimling J, Post M and Rosant J: **The basic-helix-loop-helix protein pod1 is critically important for kidney and lung organogenesis.** *Development* 1999, **126**:5771-83.
 128. Tamura M, Kanno Y, Chuma S, Saito T and Nakatsuji N: **Pod-1/Capsulin shows a sex- and stage-dependent expression pattern in the mouse gonad development and represses expression of Ad4BP/SF-I.** *Mech Dev* 2001, **102**:135-44.
 129. Kent J, Wheatley SC, Andrews JE, Sinclair AH and Koopman P: **A male-specific role for SOX9 in vertebrate sex determination.** *Development* 1996, **122**:2813-22.
 130. Shen JH and Ingraham HA: **Regulation of the orphan nuclear receptor steroidogenic factor I by Sox proteins.** *Mol Endocrinol* 2002, **16**:529-40.
 131. Viger RS, Mertineit C, Trasler JM and Nemer M: **Transcription factor GATA-4 is expressed in a sexually dimorphic pattern during mouse gonadal development and is a potent activator of the Mullerian inhibiting substance promoter.** *Development* 1998, **125**:2665-75.
 132. Tremblay JJ and Viger RS: **GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements.** *Endocrinology* 2001, **142**:977-86.
 133. Nomura M, Kawabe K, Matsushita S, Oka S, Hatano O, Harada N, Nawata H and Morohashi K: **Adrenocortical and gonadal expression of the mammalian Ftz-FI gene encoding Ad4BP/SF-I is independent of pituitary control.** *J Biochem (Tokyo)* 1998, **124**:217-24.
 134. Crawford PA, Sadovsky Y, Woodson K, Lee SL and Milbrandt J: **Adrenocortical function and regulation of the steroid 21-hydroxylase gene in NGFI-B-deficient mice.** *Mol Cell Biol* 1995, **15**:4331-16.
 135. P Zhang and Mellon SH: **The orphan nuclear receptor steroidogenic factor-I regulates the cyclic adenosine 3',5'-monophosphate-mediated transcriptional activation of rat cytochrome P450c17 (17 alpha-hydroxylase/c17-20 lyase).** *Mol Endocrinol* 1996, **10**:147-58.
 136. Mamluk R, Greber Y and Meidan R: **Hormonal regulation of messenger ribonucleic acid expression for steroidogenic factor-I, steroidogenic acute regulatory protein, and cytochrome P450 side-chain cleavage in bovine luteal cells.** *Biol Reprod* 1999, **60**:628-34.
 137. Aesoy R, Mellgren G, Morohashi K and Lund J: **Activation of cAMP-dependent protein kinase increases the protein level of steroidogenic factor-I.** *Endocrinology* 2002, **143**:295-303.
 138. Chau YM, Crawford PA, Woodson KG, Polish JA, Olson LM and Sadovsky Y: **Role of steroidogenic-factor I in basal and 3',5'-cyclic adenosine monophosphate-mediated regulation of cytochrome P450 side-chain cleavage enzyme in the mouse.** *Biol Reprod* 1997, **57**:765-71.

139. Enyeart JJ, Boyd RT and Enyeart JA: **ACTH and All differentially stimulate steroid hormone orphan receptor mRNAs in adrenal cortical cells.** *Mol Cell Endocrinol* 1996, **124**:97-110.
140. Hosokawa K, Dantes A, C Schere-Levy, Barash A, Yoshida Y, Kotsuji F, Vlodavsky I and Amsterdam A: **Induction of Ad4BP/SF-1, steroidogenic acute regulatory protein, and cytochrome P450scc enzyme system expression in newly established human granulosa cell lines.** *Endocrinology* 1998, **139**:4679-87.
141. Sahut-Barnola I, Lefrancois-Martinez AM, Jean C, Veyssiere G and Martinez A: **Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice.** *Endocr Res* 2000, **26**:885-98.
142. Sugawara T, Abe S, Sakuragi N, Fujimoto Y, Nomura E, Fujieda K, Saito M and Fujimoto S: **RIP 140 modulates transcription of the steroidogenic acute regulatory protein gene through interactions with both SF-1 and DAX-1.** *Endocrinology* 2001, **142**:3570-7.
143. Zhou D, Quach KM, Yang C, Lee SY, Pohajdak B and Chen S: **PNRC: a proline-rich nuclear receptor coregulatory protein that modulates transcriptional activation of multiple nuclear receptors including orphan receptors SF1 (steroidogenic factor 1) and ERRalpha1 (estrogen related receptor alpha-1).** *Mol Endocrinol* 2000, **14**:986-98.
144. Zhou D and Chen S: **PNRC2 is a 16 kDa coactivator that interacts with nuclear receptors through an SH3-binding motif.** *Nucleic Acids Res* 2001, **29**:3939-48.
145. Kabe Y, Goto M, Shima D, Imai T, Wada T, Morohashi K, Shirakawa M, Hirose S and Handa H: **The role of human MBFI as a transcriptional coactivator.** *J Biol Chem* 1999, **274**:34196-202.
146. Borud B, Hoang T, Bakke M, Jacob AL, Lund J and Mellgren G: **The nuclear receptor coactivators p300/CBP/cointegrator-associated protein (p/CIP) and transcription intermediary factor 2 (TIF2) differentially regulate PKA-stimulated transcriptional activity of steroidogenic factor 1.** *Mol Endocrinol* 2002, **16**:757-73.
147. Jacob AL, Lund J, Martinez P and Hedin L: **Acetylation of steroidogenic factor 1 protein regulates its transcriptional activity and recruits the coactivator GCN5.** *J Biol Chem* 2001, **276**:37659-64.
148. Yan X, Mouillet JF, Ou Q and Sadovsky Y: **A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity.** *Mol Cell Biol* 2003, **23**:414-23.
149. Ou Q, Mouillet JF, Yan X, Dorn C, Crawford PA and Sadovsky Y: **The DEAD box protein DP103 is a regulator of steroidogenic factor-1.** *Mol Endocrinol* 2001, **15**:69-79.
150. Watanabe K, Clarke TR, Lane AH, Wang X and Donahoe PK: **Endogenous expression of Mullerian inhibiting substance in early postnatal rat sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites.** *Proc Natl Acad Sci U S A* 2000, **97**:1624-9.
151. Ito M, Yu R and Jameson JL: **DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita.** *Mol Cell Biol* 1997, **17**:1476-83.
152. Crawford PA, Dorn C, Sadovsky Y and Milbrandt J: **Nuclear receptor DAX-1 recruits nuclear receptor corepressor N-CoR to steroidogenic factor 1.** *Mol Cell Biol* 1998, **18**:2949-56.
153. Liu Z and Simpson ER: **Molecular mechanism for cooperation between Sp1 and steroidogenic factor-1 (SF-1) to regulate bovine CYP11A gene expression.** *Mol Cell Endocrinol* 1999, **153**:183-96.
154. Jorgensen JS and Nilson JH: **AR suppresses transcription of the LHBeta subunit by interacting with steroidogenic factor-1.** *Mol Endocrinol* 2001, **15**:1505-16.
155. Halvorson LM, Ito M, Jameson JL and Chin VW: **Steroidogenic factor-1 and early growth response protein 1 act through two composite DNA binding sites to regulate luteinizing hormone beta-subunit gene expression.** *J Biol Chem* 1998, **273**:14712-20.
156. Tremblay JJ and Drouin J: **Egr-1 is a downstream effector of GnRH and synergizes by direct interaction with Ptx1 and SF-1 to enhance luteinizing hormone beta gene transcription.** *Mol Cell Biol* 1999, **19**:2567-76.
157. Kaiser UB, Halvorson LM and Chen MT: **Sp1, steroidogenic factor 1 (SF-1), and early growth response protein 1 (egr-1) binding sites form a tripartite gonadotropin-releasing hormone response element in the rat luteinizing hormone-beta gene promoter: an integral role for SF-1.** *Mol Endocrinol* 2000, **14**:1235-45.
158. Tremblay JJ, Lanctot C and Drouin J: **The pan-pituitary activator of transcription, Ptx1 (pituitary homeobox 1), acts in synergy with SF-1 and Pit1 and is an upstream regulator of the Lim-homeodomain gene Lim3/Lhx3.** *Mol Endocrinol* 1998, **12**:428-41.
159. Tremblay JJ, Marzil A, Gauthier Y and Drouin J: **Ptx1 regulates SF-1 activity by an interaction that mimics the role of the ligand-binding domain.** *Embo J* 1999, **18**:3431-41.
160. Gizard F, Lavalley B, DeWitte F, Teissier E, Staels B and Hum DW: **The transcriptional regulating protein of 132 kDa (TRP-132) enhances P450scc gene transcription through interaction with steroidogenic factor-1 in human adrenal cells.** *J Biol Chem* 2002, **277**:39144-55.
161. Gizard F, Lavalley B, DeWitte F and Hum DW: **A novel zinc finger protein TRP-132 interacts with CBP/p300 to regulate human CYP11A1 gene expression.** *J Biol Chem* 2001, **276**:33881-33892.
162. Liu Z and Simpson ER: **Steroidogenic factor 1 (SF-1) and SPI are required for regulation of bovine CYP11A gene expression in bovine luteal cells and adrenal Y1 cells.** *Mol Endocrinol* 1997, **11**:127-37.
163. Ito M, Park Y, Weck J, Mayo KE and Jameson JL: **Synergistic activation of the inhibin alpha-promoter by steroidogenic factor-1 and cyclic adenosine 3',5'-monophosphate.** *Mol Endocrinol* 2000, **14**:66-81.
164. Carlone DL and Richards JS: **Evidence that functional interactions of CREB and SF-1 mediate hormone regulated expression of the aromatase gene in granulosa cells and constitutive expression in R2C cells.** *J Steroid Biochem Mol Biol* 1997, **61**:223-31.
165. Chan HM and La Thangue NB: **p300/CBP proteins: HATs for transcriptional bridges and scaffolds.** *J Cell Science* 2001, **114**:2363-2373.
166. Muscatelli F, Strom TM, Walker AP, Zanaria E, Recan D, Meindl A, Bardoni B, Guioli S, Zehetner G and Rabi W et al.: **Mutations in the DAX-1 gene give rise to both X-linked adrenal hypoplasia congenita and hypogonadotropic hypogonadism.** *Nature* 1994, **372**:672-6.
167. Zanaria E, Muscatelli F, Bardoni B, Strom TM, Guioli S, Guo W, Lalli E, Moser C, Walker AP and McCabe ER et al.: **An unusual member of the nuclear hormone receptor superfamily responsible for X-linked adrenal hypoplasia congenita.** *Nature* 1994, **372**:635-41.
168. Bardoni B, Zanaria E, Guioli S, Florida G, Worley KC, Tonini G, Ferrante E, Chiumello G, McCabe ER and Fraccaro M et al.: **A dosage sensitive locus at chromosome Xp21 is involved in male to female sex reversal.** *Nat Genet* 1994, **7**:497-501.
169. Zanaria E, Bardoni B, Dabovic B, Calvari V, Fraccaro M, Zuffardi O and Camerino G: **Xp duplications and sex reversal.** *Philos Trans R Soc Lond B Biol Sci* 1995, **350**:291-6.
170. Swain A, Narvaez V, Burgoyne P, Camerino G and Lovell-Badge R: **Dax1 antagonizes Sry action in mammalian sex determination.** *Nature* 1998, **391**:761-7.
171. Achermann JC, Meeks JJ and Jameson JL: **Phenotypic spectrum of mutations in DAX-1 and SF-1.** *Mol Cell Endocrinol* 2001, **185**:17-25.
172. Swain A, Zanaria E, Hacker A, Lovell-Badge R and Camerino G: **Mouse Dax1 expression is consistent with a role in sex determination as well as in adrenal and hypothalamus function.** *Nat Genet* 1996, **12**:404-9.
173. Ikeda Y, Swain A, Weber TJ, Hentges KE, Zanaria E, Lalli E, Tamai KT, Sassone-Corsi P, Lovell-Badge R and Camerino G et al.: **Steroidogenic factor 1 and Dax-1 colocalize in multiple cell lineages: potential links in endocrine development.** *Mol Endocrinol* 1996, **10**:1261-72.
174. Lalli E, Bardoni B, Zazopoulos E, Wurtz JM, Strom TM, Moras D and Sassone-Corsi P: **A transcriptional silencing domain in DAX-1 whose mutation causes adrenal hypoplasia congenita.** *Mol Endocrinol* 1997, **11**:1950-60.
175. Lalli E, Melner MH, Stocco DM and Sassone-Corsi P: **DAX-1 blocks steroid production at multiple levels.** *Endocrinology* 1998, **139**:4237-43.

176. Zazopoulos E, Lalli E, Stocco DM and Sassone-Corsi P: **DNA binding and transcriptional repression by DAX-1 blocks steroidogenesis.** *Nature* 1997, **390**:311-315.
177. Suzuki T, Kasahara M, Yoshioka H, Umesono K and Morohashi K: **LXXLL motifs in Dax-1 have target specificity for the orphan nuclear receptors Ad4BP/SF-1 and LRH-1.** *Endocr Res* 2002, **28**:537.
178. Altincicek B, Tenbaum SP, Dressel U, Thormeyer D, Renkawitz R and Banihmad A: **Interaction of the corepressor Alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal hypoplasia congenita.** *J Biol Chem* 2000, **275**:7662-7.
179. Yu RN, Ito M, Saunders TL, Camper SA and Jameson JL: **Role of Ahch in gonadal development and gametogenesis.** *Nat Genet* 1998, **20**:353-7.
180. Babu PS, Bavers DL, Beuschlein F, Shah S, Jeffs B, Jameson JL and Hammer GD: **Interaction between Dax-1 and steroidogenic factor-1 in vivo: increased adrenal responsiveness to ACTH in the absence of Dax-1.** *Endocrinology* 2002, **143**:665-73.
181. Richards JS: **New signaling pathways for hormones and cyclic adenosine 3',5'-monophosphate action in endocrine cells.** *Mol Endocrinol* 2001, **15**:209-18.
182. Gyles SL, Burns CJ, Whitehouse BJ, Sugden D, Marsh PJ, Persaud SJ and Jones PM: **ERKs regulate cyclic AMP-induced steroid synthesis through transcription of the steroidogenic acute regulatory (StAR) gene.** *J Biol Chem* 2001, **276**:34888-95.
183. Sewer MB and Waterman MR: **Adrenocorticotropin/cyclic adenosine 3',5'-monophosphate-mediated transcription of the human CYP17 gene in the adrenal cortex is dependent on phosphatase activity.** *Endocrinology* 2002, **143**:1769-77.
184. Jones PM, Sayed SB, Persaud SJ, Burns CJ, Gyles S and Whitehouse BJ: **Cyclic AMP-induced expression of steroidogenic acute regulatory protein is dependent upon phosphoprotein phosphatase activities.** *J Mol Endocrinol* 2000, **24**:233-239.
185. Sewer MB and Waterman MR: **cAMP-dependent protein kinase (PKA) enhances CYP17 transcription via MKP-1 activation in H295R human adrenocortical cells.** *J Biol Chem* 2002, **277**:27.
186. Fu M, Wang C, Wang J, Zhang X, Sakamaki T, Yeung YG, Chang C, Hopp T, Fuqua SA and Jaffray E et al.: **Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function.** *Mol Cell Biol* 2002, **22**:3373-3388.
187. Hoyle C, Narvaez V, Alldus G, R Lovell-Badge and Swain A: **Dax1 expression is dependent on steroidogenic factor 1 in the developing gonad.** *Mol Endocrinol* 2002, **16**:747-56.
188. Clemens JW, Lala DS, Parker KL and Richards JS: **Steroidogenic factor-1 binding and transcriptional activity of the cholesterol side-chain cleavage promoter in rat granulosa cells.** *Endocrinology* 1994, **134**:1499-508.
189. Leers-Sucheta S, Morohashi K, Mason JJ and Melner MH: **Synergistic activation of the human type II 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase promoter by the transcription factor steroidogenic factor-1/adrenal 4-binding protein and phorbol ester.** *J Biol Chem* 1997, **272**:7960-7.
190. Tee MK, Babalola GO, Aza-Blanc P, Speck M, Gitelman SE and Miller WL: **A promoter within intron 35 of the human C4A gene initiates abundant adrenal-specific transcription of a 1 kb RNA: location of a cryptic CYP21 promoter element?** *Hum Mol Genet* 1995, **4**:2109-16.
191. Takayama K, Morohashi K, Honda S, Hara N and Omura T: **Contribution of Ad4BP, a steroidogenic cell-specific transcription factor, to regulation of the human CYP11A and bovine CYP11B genes through their distal promoters.** *J Biochem (Tokyo)* 1994, **116**:193-203.
192. Morohashi K, Zanger UM, Honda S, Hara M, Waterman MR and Omura T: **Activation of CYP11A and CYP11B gene promoters by the steroidogenic cell-specific transcription factor, Ad4BP.** *Mol Endocrinol* 1993, **7**:196-204.
193. Lynch JP, Lala DS, Peluso JJ, Luo W, Parker KL and White BA: **Steroidogenic factor 1, an orphan nuclear receptor, regulates the expression of the rat aromatase gene in gonadal tissues.** *Mol Endocrinol* 1993, **7**:776-86.
194. Young M and McPhaul MJ: **A steroidogenic factor-1-binding site and cyclic adenosine 3',5'-monophosphate response element-like elements are required for the activity of the rat aromatase promoter in rat Leydig tumor cell lines.** *Endocrinology* 1998, **139**:5082-93.
195. Cao G, Garcia CK, Wyne KL, Schultz RA, Parker KL and Hobbs HH: **Structure and localization of the human gene encoding SR-BI/CLA-1. Evidence for transcriptional control by steroidogenic factor 1.** *J Biol Chem* 1997, **272**:33068-76.
196. Lopez D, Sandhoff TW and McLean MP: **Steroidogenic factor-1 mediates cyclic 3',5'-adenosine monophosphate regulation of the high density lipoprotein receptor.** *Endocrinology* 1999, **140**:3034-44.
197. Lopez D, Nackle AC, W Shea-Eaton, Xue J, Schimmer BP and McLean MP: **Effects of mutating different steroidogenic factor-1 protein regions on gene regulation.** *Endocrine* 2001, **14**:353-62.
198. Lopez D, Shea-Eaton W, Sanchez MD and McLean MP: **DAX-1 represses the high-density lipoprotein receptor through interaction with positive regulators sterol regulatory element-binding protein-1a and steroidogenic factor-1.** *Endocrinology* 2001, **142**:5097-106.
199. Lopez D, Shea-Eaton W and McLean MP: **Characterization of a steroidogenic factor-1-binding site found in promoter of sterol carrier protein-2 gene.** *Endocrine* 2001, **14**:253-61.
200. Sugawara T, Kiriakidou M, McAllister JM, Kallen CB and Strauss JF 3rd: **Multiple steroidogenic factor 1 binding elements in the human steroidogenic acute regulatory protein gene 5'-flanking region are required for maximal promoter activity and cyclic AMP responsiveness.** *Biochemistry* 1997, **36**:7249-55.
201. Sugawara T, Kiriakidou M, McAllister JM, Holt JA, Arakane F and Strauss JF 3rd: **Regulation of expression of the steroidogenic acute regulatory protein (StAR) gene: a central role for steroidogenic factor 1.** *Steroids* 1997, **62**:5-9.
202. Sugawara T, Saito M and Fujimoto S: **Sp1 and SF-1 interact and cooperate in the regulation of human steroidogenic acute regulatory protein gene expression.** *Endocrinology* 2000, **141**:2895-903.
203. Brand C, Nury D, Chambaz EM, Feige JJ and Bailly S: **Transcriptional regulation of the gene encoding the StAR protein in the human adrenocortical cell line, H295R by cAMP and TGFbeta1.** *Endocr Res* 2000, **26**:1045-53.
204. Sandhoff TW, Hales DB, Hales KH and McLean MP: **Transcriptional regulation of the rat steroidogenic acute regulatory protein gene by steroidogenic factor 1.** *Endocrinology* 1998, **139**:4820-31.
205. Rust W, Stedronsky K, Tillmann G, Morley S, Walther N and Ivell R: **The role of SF-1/Ad4BP in the control of the bovine gene for the steroidogenic acute regulatory (StAR) protein.** *J Mol Endocrinol* 1998, **21**:189-200.
206. Naville D, Penhoat A, Marchal R, Durand P and Begeot M: **SF-1 and the transcriptional regulation of the human ACTH receptor gene.** *Endocr Res* 1998, **24**:391-5.
207. Naville D, Penhoat A, Durand P and Begeot M: **Three steroidogenic factor-1 binding elements are required for constitutive and cAMP-regulated expression of the human adrenocorticotropin receptor gene.** *Biochem Biophys Res Commun* 1999, **255**:28-33.
208. King PJ and Clark AJ: **Analysis of the first exon of the murine ACTH receptor gene.** *Endocr Res* 1998, **24**:397-402.
209. Heckert LL: **Activation of the rat follicle-stimulating hormone receptor promoter by steroidogenic factor 1 is blocked by protein kinase a and requires upstream stimulatory factor binding to a proximal E box element.** *Mol Endocrinol* 2001, **15**:704-15.
210. Chen S, Shi H, Liu X and Segaloff DL: **Multiple elements and protein factors coordinate the basal and cyclic adenosine 3',5'-monophosphate-induced transcription of the lutropin receptor gene in rat granulosa cells.** *Endocrinology* 1999, **140**:2100-9.
211. Duval DL, Nelson SE and Clay CM: **A binding site for steroidogenic factor-1 is part of a complex enhancer that mediates expression of the murine gonadotropin-releasing hormone receptor gene.** *Biol Reprod* 1997, **56**:160-8.
212. Duval DL, Nelson SE and Clay CM: **The tripartite basal enhancer of the gonadotropin-releasing hormone (GnRH) receptor gene promoter regulates cell-specific expression through a novel GnRH receptor activating sequence.** *Mol Endocrinol* 1997, **11**:1814-21.
213. Dorn C, Ou Q, Svaren J, Crawford PA and Sadovsky Y: **Activation of luteinizing hormone beta gene by gonadotropin-releasing hormone requires the synergy of early growth response-1 and steroidogenic factor-1.** *J Biol Chem* 1999, **274**:13870-6.

214. Halvorson LM, Kaiser UB and Chin WW: **The protein kinase C system acts through the early growth response protein 1 to increase LHbeta gene expression in synergy with steroidogenic factor-1.** *Mol Endocrinol* 1999, **13**:106-16.
215. Fowkes RC, King P and Burrin JM: **Regulation of human glycoprotein hormone alpha-subunit gene transcription in LbetaT2 gonadotropes by protein kinase C and extracellular signal-regulated kinase 1/2.** *Biol Reprod* 2002, **67**:725-34.
216. Wehrenberg U, Ivell R, Jansen M, von Goedecke S and Walther N: **Two orphan receptors binding to a common site are involved in the regulation of the oxytocin gene in the bovine ovary.** *Proc Natl Acad Sci U S A* 1994, **91**:1440-4.
217. Wehrenberg U, von Goedecke S, Ivell R and Walther N: **The orphan receptor SF-1 binds to the COUP-like element in the promoter of the actively transcribed oxytocin gene.** *J Neuroendocrinol* 1994, **6**:1-4.
218. Hu Z, Zhuang L, Guan X, Meng J and Dufau ML: **Steroidogenic factor-1 is an essential transcriptional activator for gonad-specific expression of promoter 1 of the rat prolactin receptor gene.** *J Biol Chem* 1997, **272**:14263-71.
219. Burris TP, Guo W, Le T and McCabe ER: **Identification of a putative steroidogenic factor-1 response element in the DAX-1 promoter.** *Biochem Biophys Res Commun* 1995, **214**:576-81.
220. Vilain E, Guo W, Zhang YH and McCabe ER: **DAX1 gene expression upregulated by steroidogenic factor 1 in an adrenocortical carcinoma cell line.** *Biochem Mol Med* 1997, **61**:1-8.
221. Yu RN, Ito M and Jameson JL: **The murine Dax-1 promoter is stimulated by SF-1 (steroidogenic factor-1) and inhibited by COUP-TF (chicken ovalbumin upstream promoter-transcription factor) via a composite nuclear receptor-regulatory element.** *Mol Endocrinol* 1998, **12**:1010-22.
222. Sewer MB, Nguyen VQ, Huang CJ, Tucker PW, Kagawa N and Waterman MR: **Transcriptional activation of human CYP17 in H295R adrenocortical cells depends on complex formation among p54(nrb)/NonO, protein-associated splicing factor, and SF-1, a complex that also participates in repression of transcription.** *Endocrinology* 2002, **143**:1280-90.
223. Gurates B, Sebastian S, Yang S, Zhou J, Tamura M, Fang Z, Suzuki T, Sasano H and Bulun SE: **WT1 and DAX-1 inhibit aromatase P450 expression in human endometrial and endometriotic stromal cells.** *J Clin Endocrinol Metab* 2002, **87**:4369-77.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp